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Abstract 
Human Papillomavirus positive (HPV+) head and neck squamous cell 
carcinoma (HNSCC) represents a distinct clinical and epidemiological entity 
compared with HPV negative (HPV-) HNSCC. In this thesis I conducted both 
an epigenomic and genomic analysis to test the possible involvement of 
epigenetic modulation by HPV in HNSCC and associated genetic changes. 
Using laser-capture microdissection of formalin-fixed paraffin-
embedded (FFPE) HNSCCs, I generated both DNA methylation and genetic 
profiles of HPV+ and HPV– samples. I then used an independent clinical 
sample set and HPV+ and HPV- HNSCC cell lines for the validation of the 
obtained methylation data by two independent methods (Infinium 450k 
BeadArray and MeDIP-seq). Paired end sequencing of captured DNA, 
representing 3,230 exons in 182 genes often mutated in cancer was applied 
for mutation profiling. I validated the latter findings by Infinium copy number 
variation (CNV) profiling, Sequenom MassArray sequencing and 
immunohistochemistry.  
Significant differences in the methylation and genomic profiles 
between HPV+ and HPV- HNSCC were observed. Methylation analysis 
revealed a hypermethylation signature with involvement of Cadherins of 
Polycomb group target genes in HPV+ HNSCC samples. Integration with 
independent expression data showed strong negative correlation, especially 
for the Cadherin gene family members. Combinatorial ectopic expression of 
the two HPV oncogenes (E6 and E7) in an HPV– HNSCC cell line partially 
phenocopied the hypermethylation signature observed in HPV+ HNSCC 
tumours and established E6 as the main viral effector gene. Moreover, 
MeDIP-Seq data revealed methylation sites within integrated HPV genomes. 
These methylation sites were confirmed by bisulfite sequencing, both in 
HNSCC samples and HPV+ HNSCC cell lines. Validated genomic changes 
clustered HPV+ and HPV- oropharyngeal carcinomas into two distinct 
subgroups with TP53 mutations detected in 100% of HPV- cases. Abrogation 
of the G1/S checkpoint by CCND1 amplification and CDKN2A loss occurred 
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in the majority of HPV- tumours, indicating that trials with CDK inhibitors in 
this disease subtype may be warranted.  
 My data establish archival FFPE tissue to be highly suitable for these 
types of methylation and mutation analysis and suggest that HPV modulates 
the HNSCC epigenome through hypermethylation of Polycomb repressive 
complex 2 target genes such as Cadherins which are implicated in tumour 
progression and metastasis. Moreover, my findings reinforce the causal role 
of HPV in oropharyngeal cancer and indicate that therapeutic stratification 
according to somatic genomic changes, in addition to HPV status, could be 
the most appropriate future approach for these cancers. 
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1. Chapter 1: General Introduction 
 
 
Chapter 1 
 
General Introduction 
 
This chapter provides an introduction into cancer genomics and epigenomics, 
the background to head and neck cancer and gives an overview of the 
literature that has bearing on the work in this thesis, having led me to the 
formulations of the hypotheses and objectives of the presented work. 
 
1.1 The role of HPV in Head and Neck Cancer. 
 
Head and neck cancer is the sixth most common cancer worldwide with an 
incidence of around 600,000 cases per annum, with rising trends particularly 
in the young [1, 2]. Despite recent advances in the treatment and in the 
understanding of its biology, the 5-year survival rate of 50% for patients with 
head and neck cancer on the whole has remained largely unchanged for the 
past three decades with relatively few advances since the 1990s [3]. The 
most common type of head and neck cancer is squamous cell carcinoma 
(HNSCC).  
As an umbrella term, HNSCC includes cancers found at several locations, 
e.g. in the oral cavity, pharynx and larynx. Although these cancers have 
different aetiologies and prognoses, they share similar risk factors. These 
major risk factors include the smoking and chewing of tobacco as well as 
alcohol consumption [1]. Heavy smokers under the age of 46 have a 20-fold 
increased risk of oral and pharyngeal cancer, whereas heavy drinkers are 
reported to have a 5-fold increased risk [4]. A combination of heavy smoking 
and drinking leads to an almost 50-fold increased risk of oral and pharyngeal 
cancer (ibid). However, a proportion of HNSCC patients (up to 20%) have 
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little or no tobacco or alcohol exposure, indicating other risk factors for the 
disease. 
Over recent years human papillomavirus (henceforth HPV) has been shown 
to represent a major independent risk factor for HNSCC [5, 6]. HPV is 
particularly associated with oropharyngeal carcinoma (HNSCC of the tonsils 
and base of tongue) of which 20-50% test positive for the HPV-16 subtype [5-
7]. HPV-positive HNSCC appears distinct from HPV-negative HNSCC with 
regard to the genetic mutation and gene expression status as well as to 
epidemiological factors and clinical features, leading to the conclusion that 
HPV-positive HNSCC represents a distinct molecular, epidemiologic and 
clinical entity [8, 9]. 
 
Epidemiological differences include the fact that HPV+ HNSCC is also 
increasing in the developed Western World and especially in younger age 
groups. Both HPV+ and HPV- HNSCCs occur more frequently in men at a 
rate of 3 to 1 compared to women [1, 2]. The increasing rate of squamous 
cell cancer of the tonsils and of the tongue base is particularly evident in 
patients under the age of 45 and this group has experienced a 2% per year 
increase in base of tongue cancer and a 4% per year increase in tonsillar 
cancer between 1973 and 2004. In contrast, the rates for cancers at all other 
head and neck sites during the same period remained constant or decreased 
[10]. This trend is also underscored by a further study investigating archived 
tonsil cancer specimens: HPV DNA was isolated in 23% of the specimens 
from the 1970s, 28% of the specimens of the 1980s, 57% from the 1990s, 
and 68% of specimens since 2000, showing an almost 3-fold increase [11]. A 
recently published study by the same research group suggests that the 
incidence of HPV-associated tonsillar carcinoma has even increased further 
from 2003 to 2007 (with 68% 2000-2002 to even 93% 2006-2007) with a 
parallel decline of HPV-negative tumours. Taking into account the previously 
presented data the incidence of HPV positive tonsillar tumours has almost 
doubled each decade between 1970 and 2007, suggesting an epidemic of 
viral-induced carcinoma [12]. 
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HPV related head and neck cancer more frequently occurs in younger 
patients (age <50 years) with minimal tobacco and/or alcohol exposure but 
greater exposure to oral sex, multiple sexual partners, or marijuana [13]. 
Compared to non-HPV associated head and neck cancer patients, HPV-
positive head and neck cancer patients are often of higher socioeconomic 
status with better nutritional status, dentition and overall health compared to 
patients suffering from HPV-negative head and neck cancer. Racial 
differences for HPV related head and neck cancer have also been 
demonstrated. In their study, Settle et al. found that 35% of Caucasian 
patients developed HPV-positive tumours compared with only 4% of patients 
of African origin, explaining the differences in overall survival observed 
between the two groups [14].       
In summary, the epidemiological trend suggests that HPV-related 
oropharyngeal squamous cell cancer is becoming more widespread at a time 
when the overall incidence of HNSCC is falling and this subtype typically 
occurs in younger patients (age <50 years). 
Moreover, this has major clinical implications. HPV+ HNSCC responds better 
to chemotherapy and radiotherapy (82% versus 55% response rate for HPV– 
cases) and has a better disease-free and overall survival (95% versus 62% 
at 2 years) [15]. Individuals with HPV+ HNSCC have a lower rate of second 
primary tumours, as well as a decreased cumulative incidence of relapse [16, 
17]. Thus, knowledge of a patient’s HPV status offers the possibility to stratify 
such patients for treatment and to elucidate the mechanisms underlying the 
virus-associated advantage in drug response and survival in HNSCC.  
 
A summary of the distinct molecular, epidemiological and clinical features is 
provided in Table 1.1. 
 
The causes responsible for the different clinical behaviour between HPV+ 
and HPV– tumours remain poorly understood. Numerous studies comparing 
gene expression patterns of HPV+ and HPV– cancers have shown different 
profiles between the two groups [18-22]. It is therefore likely that virus-
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mediated changes in both the genome and epigenome account for the 
differing clinical behaviour.  
 
 HPV+ HNSCC HPV- HNSCC 
Molecular  
factors 
 TP53 wild-type present in 
most cases (if TP53 
mutations are present, they 
are usually not disruptive 
[23]) 
 TP53 loss of function 
(rendered by the viral 
oncoprotein E6) [24].   
 RB1 loss of function 
(rendered by the viral 
oncoprotein E7) [25] 
 CDKN2A(p16) 
overexpression [26] 
 HPV DNA (type 16 in up to 
85% of cases) [5, 27, 28] 
 TP53 mutational loss 
(disruptive) common [23] 
 CDKN2A(p16) 
underexpression [26] 
or mutational loss [26, 29] 
 No HPV DNA/RNA 
Possible 
epidemiological  
factors 
 Often non-smokers [5, 13] 
 Mild/moderate alcohol 
intake   [5, 13] 
 High marijuana exposure 
[13] 
 Intact dentition [13] 
 High oral sex exposure [5, 
13] 
 Younger age (<45 years) 
[30, 31] 
 Increasing incidence of the 
disease [12, 32]  
 Heavy smokers [5, 13] 
 Heavy alcohol intake [5, 13] 
 Low marijuana exposure 
[13] 
 Poor dentition [13] 
 No association with sexual  
behaviours [5, 13] 
 Older age (>50 years) [30, 
31] 
 Decreasing incidence of the 
disease [12, 32]  
Clinical  
factors 
 Predominantly oropharynx  
(tonsil and tongue base) [5-
7] 
 Better survival [15, 33] 
 More radiosensitive [15] 
 All head and neck sites [5-7] 
 Worse survival [15, 33] 
 Radiation response  
unpredictable [15] 
Table 1.1: Distinct molecular, epidemiological and clinical features of HPV+ HNSCC, 
compared with HPV- HNSCC (adapted from [9]).  
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1.2 HPV-driven carcinogenesis – Current models in 
head and neck cancer. 
 
Human papillomavirus is a ubiquitous, nonenveloped, circular, double-
stranded DNA virus. It is believed that HPV represents the most common 
cause of cancers induced by an infectious agent [34]. Of the over 30 - 40 
known types of HPV that are typically transmitted by sexual contact (of more 
than 100 types of human papillomavirus; see Appendix Figure A.1), mainly 
‘high risk’ types (at least 15), such as HPV type 16 and 18, have been shown 
to promote malignant transformation. In HPV related head and neck cancer 
HPV type 16 is most frequently found (in over 85% of cases), thus 
representing the most important HPV subtype in this form of cancer [41], [28]. 
The viral genome (Figure 1.1) which uses the host DNA machinery to 
replicate and proliferate is around 8000 base pairs in length and encodes for 
only a few gene products: 6 early proteins (incl. the oncoproteins E6 and E7, 
proteins required for DNA amplification, such as E4 and E5 and the two 
regulatory proteins E1 and E2, which also play a role in DNA replication) as 
well as two late proteins (L1 and L2, representing the two structural capsid 
proteins) [35]. The HPV life cycle is complex and coupled to the cellular 
differentiation programme that occurs in the epithelium (Figure 1.1). 
Through microabrasions in the skin and mucous membranes, HPV infects 
cells in the basal layer of the stratified epithelium where they establish their 
double-stranded DNA genome as a circular extrachromosomal element in the 
nucleus of infected cells (nuclear episome). In cervical lesions DNA is 
thought to be present at low copy numbers with 50-100 copies per infected 
cell during the early stage of infection (required to sustain the viral life cycle 
and its associated pathologies) [36]. In the upper layers of the epithelium 
HPV DNA is then amplified to greater than 1000 copies per cell [37], having 
been tested in raft cultures of human keratinocytes. In the terminally 
differentiated epithelial cells the capsid proteins are expressed and progeny 
virions are assembled. These virions are then shed [25]. 
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Figure 1.1:  Genome of HPV type 16 (A) and illustration of the virus life cycle (B). The above 
figure was obtained from [25]. (A) Early (p97) and late (p670) promoters are marked by 
arrows within the HPV type 16 genome (7904 bp in length). The six early ORFs (E1, E2, E4 
and E5 are shown in green and E6 and E7 in red) are expressed from either p97 or p670 at 
different stages during epithelial cell differentiation, whereas the late ORFs (L1 and L2, 
shown in yellow) are only expressed from p670 (B). Within the long control region (7156–
7184 bp) E2-binding sites and the TATA element of the p97 promoter are illustrated. (B) Key 
events following infection are shown diagrammatically within the epidermis (both in 
cutaneous tissue and within mucous membranes). Virus infection, and in particular, the 
expression of the viral oncogenes, E6 and E7, lead to the appearance of cells expressing 
cell cycle markers in the basal layer of the epidermis (shown with red nuclei). In these cells 
the expression of viral proteins necessary for genome replication then follows the activation 
of p670 in the upper epithelial layers (cells illustrated in green with red nuclei). Expression of 
the L1 and L2 genes (shown in yellow) occur only in a subset of the cells that contain 
amplified viral DNA in the upper epithelial layer (Figure Legend adapted from [25])  
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Integration of the virus is frequently observed in HPV-associated cancers [38, 
39]. Integration is thought to disrupt the regulation of E6 and E7 expression 
and to subsequently lead to higher expression levels of these oncoproteins 
with the effects described above [25]. 
HPV+ HNSCC is characterized by distinct molecular pathways which are 
different from those involved in HPV- HNSCC [8]. The important role of high-
risk HPV oncoproteins, in particular E6 and E7, in malignant transformation 
and the maintenance of this malignant phenotype is well recognized, having 
been described in cervical cancer first [25]. 
Current model of HPV+ and HPV- HNSCC carcinogenesis: 
As described above, integration of the HPV into the host genome is found in 
HNSCC and the HPV genome is interrupted by the integration event. Upon 
integration E5 function is frequently lost and thus, E5 is not regarded as 
being a mediator in late stage carcinogenesis [40]. However, the HPV E5 
protein is thought to play an important role during the early stage of infection 
by binding epidermal growth factor receptor (EGFR), platelet derived growth 
factor receptor beta polypeptide (PDGFRB) and colony stimulating factor 1 
receptor (CSF1R), thereby promoting cell proliferation [41]. The same applies 
to the E2 gene which lies in the same region and is a potent inhibitor of E6 
and E7 viral gene expression. E2-mediated inhibition is also frequently lost 
upon integration of HPV into the host genome, as described in cervical 
cancer [42]. 
The main mechanism by which HPV causes cancer is the expression of the 
two viral oncoproteins E6 and E7. These oncoproteins degrade and 
destabilize two major tumour suppressor proteins of the host, tumour protein 
p53 (TP53) and retinoblastoma 1 (RB1), through ubiquitination. The HPV E6 
protein forms a complex with an E3 ubiquitin ligase (UBE3A, also referred to 
as E6AP), and ubiquitinates TP53 [43-45]. This ubiquitination leads to rapid 
degradation of TP53, which results in deregulation of both the G1/S and 
G2/M cell cycle checkpoints during cell damage and other cellular stress, 
which leads to genomic instability [46]. The HPV E7 oncoprotein ubiquinates 
RB1 by binding to the cullin 2 ubiquitin ligase complex [47-49]. Ubiquination 
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of RB1 results in its degradation leading to deregulation of the G1/S phase of 
the cell cycle. The absence of RB1 then causes the release of the E2F family 
of transcription factors with the transcription of S-phase genes, resulting in 
cell proliferation [50].  
A summary of the cell cycle deregulation by human papillomavirus is 
illustrated in Figure 1.2 (from [51]). 
Figure 1.2: Cell cycle deregulation by human papillomavirus (adapted from [51]). Effects of 
the two main viral oncoproteins on TP53 and RB1 function and cell-cycle regulation are 
illustrated. 
Moreover, studies have shown that E6 and E7 can directly bind to numerous 
host proteins other than TP53 and RB1. These include, for example, BCL2-
antagonist/killer 1 (BAK1) and cyclin-dependent kinase inhibitor 1A 
(CDKN1A; also referred to as p21 or Cip1) [51]. This further contributes to 
genetic instability. However, many more genetic alterations are necessary for 
malignant progression in the setting of virus-induced genomic instability. 
Most of these are currently unknown [52]. 
Looking at the most well studied example of HPV-induced cancer, cervical 
cancer, the period of time from the initial infection with a high-risk type of 
HPV to malignant transformation and the development of cervical cancer is 
typically between 10 and 20 years [53]. 
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In contrast to this, HPV- HNSCC takes around 30 – 40 years to evolve, with 
multiple genomic changes and epigenomic changes in key pathways thought 
to be acquired by the exposure of the respective epithelium to carcinogens, 
instigated by smoking or alcohol abuse, and chronic inflammation. These 
genomic and epigenomic alterations are discussed in detail in section 1.3. 
A current model of the molecular carcinogenesis of HNSCC is illustrated in 
Figure 1.3 (from [51]). 
Figure 1.3: Genetic and epigenetic changes currently regarded key steps in the molecular 
carcinogenesis of HNSCC (obtained from [51]). This figure illustrates a multi-step model of 
head and neck carcinogenesis via precursor lesions. The progression from normal tissue to 
metastatic cancer is associated with an accumulation of specific genetic and epigenetic 
changes.  
 
1.3 Genetics and Epigenetics of Head and Neck Cancer. 
 
Cancer is a heterogeneous disease caused largely by the acquisition of 
biological capabilities, rendered by changes in the genome and the 
epigenome in a partly stochastic and partly directed multi-step process, with 
underlying genomic instability. These capabilities were referred to as 
hallmark capabilities by Hanahan and Weinberg [54] and are outlined in 
Figure 1.4. 
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Typically, genetic changes such as mutations and other genomic 
rearrangements or epigenetic changes such as aberrant DNA methylation 
and histone modifications underlie such abnormalities and are mediated by 
exposure to environmental or life-style factors.  
Therefore, comprehensive genetic and epigenetic analysis of cancer 
genomes is the most effective way to identify causative changes involved in 
tumourigenesis, irrespective of whether they are inherited or acquired. 
 
Figure 1.4: The 10 hallmark capabilities of cancer (obtained from [54]). 
 
1.3.1 The Cancer Epigenome of Head and Neck Cancer  
Oncogenic loci in HNSCC encompass genes which are mutated (and 
amplified/deleted) or epigenetically compromised (epimutation), for instance, 
by promoter methylation. These epigenetic changes at oncogenic loci 
associated with progression to carcinoma, particularly in HPV+ HNSCC, are 
not well characterized. 
Recent progress in technology now enables the study of these epigenetic 
variations at the genome level. The obtained profiles are called epigenomes 
and in the context of cancer are referred to as cancer epigenomes.  
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’Epigenome’ is defined as the complete set of chemical modifications of 
chromatin constituents and ‘methylome’ as the complete set of DNA 
methylation modifications of the genome. [55] Additional non-covalent 
modifications such as micro RNAs and chromatin remodelling complexes 
also modulate the epigenome (Figure 1.5). 
Compared to the genome, the epigenome is much more dynamic, reflecting 
many different functional states in time and space. These dynamics are 
governed in part by reversible covalent modifications of the epigenome such 
as DNA methylation and histone tail modifications. 
Figure 1.5: Illustration of chemical modifications of chromatin constituents (Adapted from 
[56])  
Epigenetic processes may affect both the viral genome itself and the host cell 
methylome. Modification of normal epigenetic processes in the host occurs 
during viral infection: for example, compared with HPV-negative HNSCC, 
HPV+ tumours show less genome-wide hypomethylation [57]. These 
epigenetic changes may occur through direct interactions between HPV 
proteins (e.g. E2, E7) and proteins involved in DNA methylation. Viral 
oncoproteins (in particular E7) can bind and regulate DNMT1 enzymatic 
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activity [58]. Moreover, interactions between E7 and components of the 
chromatin remodelling machinery, e.g. p300, are also described [59]. It has 
also been shown that E7 induces KDM6A and KDM6B histone demethylase 
expression and causes epigenetic reprogramming [35]. 
This research work is set in an environment in which the analysis of cancer 
genomes and epigenomes is well underway. This era of cancer genome and 
epigenome projects as part of multiple national and international efforts [56], 
[60] represent an important endeavour to understand the genetic and 
epigenetic basis of malignant disease. The recent endeavours and 
achievements, which have been massively boosted by decreasing 
sequencing costs, are summarized in Figure 1.6. 
Figure 1.6: Landmark initiatives towards comprehensive analysis of cancer (epi)genomes. 
The emergence of next-generation sequencing (indicated by blue shading) since 2004 has 
clearly galvanized the field (adapted from [55]) 
Past and present projects include the Human Epigenome Project (HEP), 
Cancer Genome Project (CGP), The Cancer Genome Atlas (TCGA), NIH 
Roadmap Epigenomics Program, International Cancer Genome Consortium 
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(ICGC), and International Human Epigenome Consortium (IHEC) (recently 
summarized in [55]). Head and neck cancer is now also one of the featured 
cancers in the Cancer Genome Atlas (TCGA) project, a main focus in 
extensive epidemiological studies, i.e. International Head and Neck Cancer 
Epidemiology (INHANCE) consortium [61] and future collaborative projects 
on head and neck cancer, such as the ‘Enabling Head and Neck Cancer 
Therapy via Novel Biomarkers (ENHANCER)’ project.  
Not only will these projects identify a whole-genome map of genetic and 
epigenetic changes that determine the phenotype of the cancer investigated, 
but also lead the development of novel diagnostic and prognostic markers, of 
drugs specifically directed to the described genetic and epigenetic changes 
(targeted and combinatorial therapies) and gain the necessary information to 
direct the therapeutics effectively and safely to the identified targets.  
The reversible nature of epigenetic aberrations has already led to the 
emergence of the promising field of epigenetic therapy (with the two groups 
of drugs targeting the epigenome, DNA methylation inhibitors and Histone 
deacetylase (HDAC) inhibitors). The aim of this new treatment option is to 
reverse epigenetic changes which contribute to carcinogenesis (driver 
epimutations) and to restore a ‘normal epigenome’. Some agents of this class 
of therapeutics (although not yet target-specific) have recently been 
approved by the FDA for cancer treatment and can be expected to play a 
major role in epigenetic cancer therapy in the future [62].  
Analysis of the epigenome is more complex than that of the genome and the 
majority of studies have therefore focused on the methylome as DNA 
methylation is the most accessible epigenetic modification in clinical samples 
[63]. 
DNA methylation refers to the addition of a methyl-group to cytosine (Figure 
1.7), catalysed by DNA (cytosine-5-)-methyltransferases (DNMTs). In 
mammals, it plays a key role in regulating gene expression and other 
biological processes such as X-chromosome inactivation in women [64], 
parent-of-origin-specific gene expression (imprinting) [65] and epigenetic 
reprogramming during mammalian development [66]. It occurs on cytosines 
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not only at CpG sites (mostly clustered in ‘islands’ that are predominantly 
found at gene promoters or in nearby ‘shores’ – regions up to several 
kilobases up- or downstream of the promoter) but also at non-CpG sites (as 
recently described [67]) across the genome. 
 
Figure 1.7: The catalysis of 5-methylcytosine from cytosine by DNA methyltransferase 
(DNMT); adapted from [68]. 
To date most studies have focused on DNA methylation at these gene 
promoters and CpG islands only, as many technologies covered these 
efficiently, such as restriction landmark genomic scanning (RLGS) [69, 70] 
and CpG island microarrays [71]. However, recent evidence suggests that 
areas outside these regions – such as the methylation of CpG island shores 
and shelves [72, 73] or of cytosines in non-CpG sites play key roles in 
cellular differentiation and thus malignant transformation. It remains unclear 
whether methylation within CpG sites in the ‘open sea’ has any significance. 
These areas of the genome were not covered by former methods, either due 
to the fact that they were not global enough or biased toward CpG islands. 
Only fairly recently have efficient technologies become available for genome-
wide methylation analysis with the introduction of the microarray and later 
second-generation sequencing, exemplified by the Roche 454 platform [74], 
35 
 
the Illumina GA platform [75] and the Applied Biosystems SOLiD platform 
[76]. These next-generation sequencing techniques have been successfully 
combined with different capture techniques for methylated DNA, resulting 
e.g. in AutoMeDIP-Seq [77] and MBD-seq [78]. These methods are now 
capable of covering around 70% of the >28 million CpG sites across the 
haploid human genome (at 50-100 bp resolution). Another method based on 
bisulfite sequencing allows methylome analysis at single base resolution [67]. 
In this thesis I applied MeDIP-Seq [77] which allowed me to interrogate 
approximately 70% of the host methylome of HNSCC and 100% of the HPV 
methylome. One of the main limitations of these techniques was that until 
recently these technologies were very expensive.  
Thus, until recently microarrays have been the most widely used tool for 
comprehensive DNA methylation analysis. Advantages of using microarrays 
include ease of use, high levels of multiplexing and parallel processing to 
facilitate high-throughput and cost-effective analysis as well as the possibility 
of capturing specific target regions for subsequent array- or sequencing 
based analysis [79]. Being essentially an analogue technology, 
disadvantages include lower sensitivity and specificity than those achievable 
by digital technologies such as sequencing. Nevertheless, the first 
methylomes to be reported were generated using microarray-based 
approaches [80], [81]. However, the introduction of next-generation 
sequencing is increasingly replacing and will continue to replace microarrays 
in the coming years. A likely exception is so-called beadarrays (e.g. in 
conjunction with the Illumina Infinium assay) which allow highly sensitive and 
quantitative methylation analysis at the single base-pair level [82]. In 2009 
Illumina announced the release of its Infinium HumanMethylation450 
BeadChip which was a big step towards its application for more 
comprehensive methylome analysis, based on Infinium® Assay used for 
analysis of CpG methylation using bisulfite-converted genomic DNA. This 
technology which was used for the host methylome analysis of HNSCC 
samples and for the validation of the obtained results, allowed me to 
interrogate > 485,000 CpG (methylation) sites per sample at a single 
nucleotide resolution. The content of CpG sites probed was selected 
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according to the guidance of a consortium of methylation experts, covering 
99% of RefSeq genes, with multiple probes per gene region distributed 
across the transcription start site, 5'UTR, first exon, gene body, and 3'UTR. It 
covers 96% of CpG islands, with additional coverage in island shores, 
shelves and the open sea. It also covers a proportion of non-CpG methylated 
sites identified in human stem cells [83]. 
The main mechanism of epigenome-induced carcinogenesis is the silencing 
of tumour suppressor genes mediated by site-specific DNA hypermethylation. 
Such genes are heavily involved in cell cycle control, apoptosis, cell 
adhesion, DNA repair, and angiogenesis (e.g. TP53, RB1, P16, PTEN, 
MLH1, and BRCA1). Their loss of function leads to the gain of hallmark 
capabilities of cancer in human cells [84]. In addition to direct effects by DNA 
hypermethylation of genes, various indirect effects exist. These include the 
silencing of effector molecules, such as transcription factors that mainly effect 
downstream targets and thereby contribute to the process of malignant 
transformation. An example includes the silencing of the transcription factor 
RUNX3 in oesophageal cancer [85]. The Knudson two-hit model in the 
context of DNA methylation describes a model in which one allele of a 
tumour suppressor gene is silenced, e.g. by somatic mutation, and the 
second allele is then hypermethylated, leading to a complete loss of gene 
function [86].  
DNA hyopmethylation often results in the activation of oncogenes, thus 
initiating carcinogenesis. This mechanism has been described in various 
cancers, e.g. R-RAS and MAPSIN in gastric cancer, S-100 in colon cancer 
and MAGE in melanoma [87]. In conjunction with histone modifications (e.g. 
the methylation at lysine residues 9 and 27 of histone H3), these epigenetic 
changes affect the chromatin structure through a cascade of chemical 
reactions and interactions with additional proteins and protein complexes. 
In summary, DNA hypermethylation can result in the silencing of tumour 
suppressor genes and DNA hypomethylation in the activation of oncogenes, 
thereby significantly contributing to carcinogenesis.  
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Studies, describing the methylome analysis on a selected range of cancers,  
have been reviewed in a book chapter recently [88] and I will now mainly 
focus on the current state of affairs with regard to methylome analyses of 
head and neck cancer in the following section. 
The role of DNA methylation in HNSCC:  
As with other cancer types, numerous DNA methylation changes are 
detected in head and neck cancer, suggesting an important role of 
epigenetics in head and neck carcinogenesis.  
Most studies reported to date, however, only assessed single methylation 
sites (mostly promoter regions) or covered tiny proportions of the cancer 
methylome. Studies which assessed the methylation status of single genes in 
HNSCC samples identified numerous tumour suppressor genes to be 
differentially methylated, e.g. APC [89], CDKN2A(p16) [89], MLH1 [90], and 
MSH2 [90]. Some of these, such as CDKN2A, were also shown to potentially 
have a diagnostic value when examined as a panel including further relevant 
genes in blood samples [91] and in oral and salivary rinses [91], [92]. 
However, I have identified only a few studies which investigated DNA 
methylation profiles in head and neck cancer samples. Using the Illumina 
Golden Gate assay (covering 1,536 CpG sites), Marsit et al. [93] showed that 
specific DNA methylation profiles in HNSCC are associated with certain risk 
factors such as tobacco smoking and alcohol abuse as well as tumour stage. 
Using combined bisulfite restriction analysis of the LRE1 sequence, it was 
shown that DNA hypomethylation in whole blood is associated with a 1.6-fold 
increased risk of HNSCC [94]. Only a very few studies can be identified 
which assess the methylation status of samples in the context of the HPV 
status of HNSCC. Using pyrosequencing, LINE hypomethylation was found 
to be more pronounced in HPV- than in HPV+ tumours. Genomic instability 
was found to be greater in HNSCC samples with more pronounced LINE 
hypomethylation [57]. A recent study [95] comparing two HPV+ with two 
HPV– HNSCC cell lines showed that HPV infection is associated with 
changes in methylation of various host genes. Their study identified five 
Polycomb Repressive Complex 2 (PRC2) targets among hypermethylated 
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promoters. Polycomb group (PcG) proteins are transcriptional repressors, 
modifying histone tails to reversibly suppress genes required for 
differentiation [96]. These proteins play a major role in neoplasia [97] and 
their oncogenic function is associated with a well-established role in stem cell 
maintenance. Stem cell PcG targets were shown to be 12-fold more likely to 
have cancer-specific promoter hypermethylation than non-targets [98-100], 
supporting the theory of a stem cell origin of cancer [101]. 
These described epigenetic changes that occur both in the host [102] and 
viral methylomes [103, 104], may occur through direct interactions between 
HPV proteins (e.g. E2, E7) and proteins involved in DNA methylation. Viral 
oncoproteins (in particular E7) can bind and regulate DNMT1 enzymatic 
activity [58]. Moreover, interactions between viral oncoproteins and 
components of the chromatin remodelling machinery, e.g. p300, are also 
described [59, 105].  
In summary, the analysis of cancer epigenomes in the context of HNSCC is 
still at an early stage. Most of the studies published so far have only 
assessed methylation changes in the context of CpG methylation, 
predominantly investigating the promoter regions of genes. 
Thus, the work presented in this thesis represents a significant step forward 
in the understanding of the epigenetic basis of head and neck cancer. 
1.3.2 The Cancer Genome of HNSCC – Current State of Affairs 
Early neoplastic events in up to 80% of HPV- HNSCC include the mutational 
loss of Cyclin-dependent kinase inhibitor 2A (CDKN2A; frequently referred to 
as p16) and TP53 (mainly mediated by significant alcohol and tobacco 
exposure), leading to uncontrolled cellular growth [106]. In most cases of 
HPV+ HNSCC, TP53 mutations are not found at all [23]. In these, however, 
unmutated wild-type TP53 is degraded by the E6 protein and CDKN2A (p16) 
is overexpressed [107]. Previous studies reported that HPV- tumours show 
losses at chromosomal regions 3p, 9p, and 17p, which are absent in HPV+ 
tumours [1]. It is noteworthy that 18q12.1-23 is gained in HPV+ tumours and 
lost in HPV- tumours [108]. Taking a broader view, HPV associated HNSCC 
show fewer genome-wide DNA copy number alterations [108], less genome-
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wide hypomethylation [57], and lower expression of EGFR [109]. Two recent 
Science papers investigated the genomic profile of HNSCC, but both only 
included a very small number of HPV+ samples. Stransky et al. [110] looked 
at 74 samples (final number for analysis) of which 11 were from the 
oropharynx (7 HPV+ and 4 HPV-), not checking for copy number alterations. 
Agrawal et al. [111] tested 32 samples for HPV (4 HPV+ samples and 28 
HPV- samples). The average number of mutations in HPV+ samples were 
4.8 and in HPV- 20.6. The main copy number alterations observed in their 
study are illustrated in Table 1.2. 
 
Table 1.2: Copy number alterations observed in HNSCC (Adapted from Supplemental Table 
S.7 [111])  
In summary, these studies showed that over 80% of tumours contain TP53 
mutations (a potential genomic stratifier for HPV status) and strikingly up to 
20% have loss-of-function NOTCH1 mutations. However, in these two 
studies, only seven and four HPV+ samples were included respectively. Both 
studies confirmed the lack of TP53 mutations compared to HPV- samples, 
and overall, a lower mutational burden in HPV+ disease. 
1.3.3 Gene expression changes between HPV+ and HPV- head and 
neck cancer 
Five studies are identified which evaluated gene expression changes in 
HPV+, compared with HPV- head and neck cancers [18, 20-22, 26]. In their 
gene expression analysis, Jung et al. [26] found the most significantly 
differentially expressed gene to be cyclin-dependant kinase inhibitor 2A 
(CDKN2A or often referred to as p16), a known biomarker for HPV+ HNSCC 
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[112]. All studies show clear differences in the gene expression between 
HPV+ and HPV- HNSCC. 
 
1.4 The Epigenome of HPV in HNSCC. 
 
As described in section 1.1, HPV type 16 is most frequently found (in over 
85% of cases) in HPV+ HNSCC and thus the focus shall lie on this high-risk 
type. 
Not only do epigenetic processes affect the host genome, but also the viral 
genome itself. The HPV genome does not encode for any DNA 
methyltransferases (DNMT) and thus it is believed that the viral genome is 
methylated by the human host cell DNMTs [104]. This may either be directed 
by the virus through cross-talk between viral proteins and DNMTs (in order to 
regulate intrinsic cell-differentiation dependent and temporal viral gene 
expression) or it may represent a potential host defence mechanism, with the 
host aiming to alter viral gene expression once the virus integrated into the 
host genome. By micro-dissecting cell fractions and isolating DNA from the 
basal, intermediate, and superficial epithelial cell layers of HPV type 16 
positive cervical biopsy sections, S. Vinokurova et al. detected differential 
methylation of transcription factor binding sites within the HPV 16 upstream 
regulatory region which were associated with the squamous epithelial 
differentiation stage. This is an indicator that methylation of the HPV type 16 
genome is linked to differentiation dependent transcription and replication 
control, thus potentially triggering neoplastic transformation [113]. 
 
In cervical epithelium, HPV DNA hypermethylation has been observed to be 
more closely associated with cervical carcinoma, than with asymptomatic 
infection or with dysplasia [103, 114]. Methylation of the L1 gene of both 
HPV-16 and of HPV-18 has previously been reported in cervical cancer and 
in penile cancer [114-117].  
 
Methylation changes within HPV-16 in HNSCC have been demonstrated by 
Balderas-Loaeza et al. [118]. Methylation of the viral genome near the 3’ end 
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of the L1 ORF (3 CpGs) and in the LCR (5 CpGs) was observed. The most 
extensive study of methylation of the HPV-16 genome in HNSCC was 
performed by Il-Seok Park et al. [119]. Using BS-Seq, they determined the 
methylation status of all 110 CpG sites within the viral genome in advanced 
stage HPV+ HNSCC. In most cases they found that the viral methylome was 
not methylated within the LCR, which controls the expression of the viral 
oncogenes E6 and E7. Methylation in other regions was detected to varying 
degrees [119].  
 
1.5 Aims of my thesis and hypotheses tested in this work. 
 
As outlined, the analysis of the cancer genome and epigenome of HPV+, 
compared with HPV- HNSCC, is still at an early stage. Most of the studies 
published to date have only assessed small proportions of the genome and 
methylome or included only a very small number of HPV+ cases which 
makes it impossible to draw definitive conclusions.  
Thus, I have formulated the following aims of this work to make a significant 
step forward in the understanding of the genetic and epigenetic basis of head 
and neck cancer 
Aims of the project: 
The overall aim of this project was to understand the genetic basis of HNSCC 
and epigenetic alterations induced by HPV, contributing to HNSCC. I 
investigated the effects of HPV infection on the host methylome (human 
HNSCC), the viral methylome (i.e. HPV) and the specific genetic changes 
associated with both subtypes. In order to achieve this I aimed to perform: 
1.) Comprehensive methylome analysis of HPV(+) and HPV(-) HNSCC,  
which informed me about detailed epigenetic changes unique to HPV 
associated head and neck cancer (both detected in the human genome as 
well as in the virus itself) and the validation of these results.  
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2.) Genomic profiling of the same samples which informed on differences in 
the mutational profiles between these two patient groups. 
3.) In vitro experiments to confirm the obtained results, and to induce the 
observed changes in in vitro models of HPV(+) and HPV(-) cancer. 
Results were linked to public gene expression array and whole-genome 
somatic mutation databases. Having integrated these data with public 
databases and having integrated my obtained data on HNSCC with those 
from other HPV-induced and smoking-induced cancers, it has advanced the 
current understanding of HPV+ HNSCC, compared with HPV- HNSCC, and 
helped to partly explain the better outcome and survival of patients suffering 
from this distinct subtype. In the longer-term, these data will be used to 
identify potential diagnostic and prognostic markers, as well as putative 
therapeutic targets. 
My workplan is outlined in Figure 1.8: The chapters of my thesis are indicated 
which are dealing with the experimental approaches set out to answer the 
following research question and to test my hypotheses. 
Research question and hypothesis: 
What is the role of HPV infection in oropharyngeal carcinoma? In particular, 
my thesis investigated the genetic and epigenetic alterations in HPV+, 
compared with HPV-HNSCC. My project also investigated the regulatory role 
of such changes, and the methylation status of HPV open reading frames 
(henceforth ORFs) in positive tumours. My thesis addressed whether such 
genetic and epigenetic differences could contribute to the better overall 
responses to chemo-radiotherapy, and better overall outcome, of HPV+ 
HNSCC.  
My hypothesis was that HPV+ HNSCC, compared with HPV- HNSCC, has a 
distinct genomic and epigenomic profile and that HPV modulates the host 
epigenome.  
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Figure 1.8: Outline of the work presented in this thesis. 
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2. Chapter 2: Materials, Methodology and 
Experimental Procedures 
Chapter 2 
 
Materials, Methodology and Experimental 
Procedures 
 
This chapter describes the materials, various methodologies and 
experimental procedures which were used in carrying out this research. 
 
2.1 Materials. 
 
2.1.1 Human Tissue Samples and Clinical Data: 
Ethical approval for the study of human tissue samples was granted by the 
UCL/UCLH Ethics Committee (Reference number 04/Q0505/59). 107 
archival formalin fixed paraffin embedded tissue (FFPE) oropharyngeal 
cancer samples were obtained from the Department of Histopathology at 
University College London Hospitals (UCLH). 82 of these samples were 
considered suitable for p16 staining after careful histopathological review. 82 
samples (77%) were stained for p16 (CDKN2A). 28 oropharyngeal cancer 
samples stained positive (34.2 %). 46 oropharyngeal cancer samples stained 
negative (56.1 %). 8 oropharyngeal cancer samples showed a mixed staining 
– a tumour sample showed both positively and negatively stained areas (9.7 
%). Laser capture microdissection was performed on 74 samples (90 %). The 
dissection and DNA extraction from these samples (yielding sufficient 
amounts of good DNA quality) was successful in 66 samples (89.2 %). E6 
qPCR was performed on 66 samples. This method was assumed to be the 
gold standard for further calculation. 24 samples were positive for E6 
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amplification (36.4 %) and 40 samples were negative for E6 amplification 
(60.6 %). 2 samples showed inconsistent or borderline results in repeat 
measurements (3 %). 64 samples were used for the final analysis. 
Considering p16 staining and confirming the results by E6 qPCR (assuming 
that E6 qPCR is the gold standard) in a total of 64 samples: true positives: 22 
(34.4 %); true negatives: 34 (53.1 %); false positives: 6 (9.4 %); false 
negatives: 2 (3.1 %). In my set of samples p16 staining had a sensitivity of 
91.6 % and a specificity of 85 % (Table 2.1). The 22 p16 and E6 qPCR 
positive and 34 p16 and qPCR negative samples were selected for further 
analysis, according to the quality and the amount of the yielded DNA and 
gender and age-matching requirements (Workflow illustrated in Figure 2.1).  
 
Table 2.1: Calculation of sensitivity and specificity of p16 staining in the set of tested 
samples.  
 
 
Figure 2.1: Workflow of FFPE sample preparation and selection. The 22 p16 and E6 qPCR 
positive and 34 p16 and qPCR negative samples were available for further analysis.  
 
Furthermore, three fresh-frozen (FF) HPV+ and three FF HPV– HNSCC 
samples (Table 2.2) were obtained from the UCLH Head and Neck Tumour 
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Bank. These three fresh-frozen HPV+ and HPV- HNSCC samples (Table 
2.3) were used for MeDIP-Seq analysis (incl. Illumina HumanOmni1-Quad 
BeadChip genotyping array for normalization of MeDIP-Seq data) as well as 
for Illumina Infinium 450k array analysis to validate FFPE findings. They were 
also used for the analysis and the validation of results of the viral methylome 
experiments. 
 
Table 2.2: Patient characteristics of 3 HPV+ and 3 HPV- fresh frozen HNSCC samples.  
 
Human Tissue samples used for the host methylation analysis (chapter 3): 
According to the quality and the amount of the yielded DNA and gender and 
age-matching requirements 21 HPV+ and 21 HPV– age-matched samples 
were selected for methylation analysis. Histological diagnosis was confirmed 
by an experienced histopathologist and correlated with clinical findings (Table 
2.3). Furthermore, the described three FF HPV+ and three FF HPV– HNSCC 
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samples (Table 2.2) were used for MeDIP-Seq analysis as well as for 
Illumina Infinium 450k array analysis to validate FFPE findings. 
 
Table 2.3: Patient characteristics of 21 HPV+ and 21 HPV- FFPE HNSCC cases used for 
the host methylome analysis. 
Human Tissue samples used for the viral methylome analysis (chapter 4): 
The above-mentioned three FF HPV+ and three FF HPV– HNSCC samples 
(Table 2.2) were obtained from the UCLH Head and Neck Tumour Bank. 
Human Tissue samples used for the genomic analysis (chapter 5): 
 According to the quality and the amount of the yielded DNA and 
gender and age-matching requirements, 20 HPV+ and 20 HPV- 
oropharyngeal carcinomas were selected, all formalin fixed paraffin-
embedded, for paired-end sequencing of hybrid-captured DNA, targeting 
3,230 exons in 182 genes often mutated in cancer. These data were 
validated by Sequenom MassArray sequencing, Infinium copy number 
variation (CNV) profiling, and immunohistochemistry (Table 2.4). 
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Table 2.4: Patient characteristics of selected HPV+ and HPV- FFPE HNSCC samples for 
NGS. 
 
2.1.2 Cell lines used for the experiments: 
HNSCC cell lines UPCI:SCC090 (HPV+), UPCI:SCC003 (HPV–), 
UPCI:SCC036 (HPV–) and PCI-30 (HPV–) were generous gifts from Dr. 
Susanne Gollin and Dr. Theresa Whiteside  (University of Pittsburgh Cancer 
Institute, US). 93VU-147T (HPV+) was a generous gift from Dr. Hans Joenje 
(VU Medical Center, Netherlands) and UM:SCC047 (HPV+) was from Dr. 
Thomas Carey (University of Michigan, US). All cell lines were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% foetal 
bovine serum (FBS) and penicillin/streptomycin. I also generated clones of 
SCC003 expressing either empty vector control, HPV-16 E7, HPV-16 E6, or 
both HPV-16 E6 and E7, respectively. 
The main features of these cell lines are described in Table 2.5. HPV status 
was confirmed by E6 and E7 qPCR as described in section 2.2.8. 
49 
 
 
Table 2.5: HPV+ and HPV- HNSCC cell lines used for experiments. 
 
2.2 Core experimental procedures. 
 
All general purpose chemicals and media were purchased from Sigma-
Aldrich (Sigma-Aldrich Company Ltd, Fancy Road, Poole, BH12 4QH) or 
BDH (BDH Laboratory Supplies, Poole, BH15 1TD) unless otherwise stated. 
2.2.1 DNA extraction: 
DNA from the fresh frozen tumour samples and HNSCC cell lines was 
extracted using the QIAamp DNA Blood Mini Kit (QIAGEN). The QIAamp 
DNA FFPE Tissue Kit (QIAGEN) was used for the DNA extraction of laser 
dissected FFPE samples. 
2.2.2 RNA extraction: 
RNA from cell lines and infected cell line clones was extracted using the 
RNeasy Plus Mini Kit (QIAGEN).  
2.2.3 DNA and RNA quantification: 
DNA and RNA were quantified using the ND-1000 Spectrophotometer 
(NanoDrop®). For sequencing experiments DNA was quantified using the 
standardized PicoGreen fluorescence assay (LifeTechnologies, Carlsbad, 
CA). 
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2.2.4 Assessment of HPV status: 
HPV status was determined by CDKN2A (p16) immunostaining (a biomarker 
for HPV+ HNSCC) of the corresponding FFPE blocks (in collaboration with 
UCL Advanced Diagnostics) and confirmation by E6 qPCR on extracted DNA 
from both fresh-frozen samples, FFPE samples, and cell line samples [120]. 
This has been shown to have 97% sensitivity, 94% specificity and to be the 
best discriminator of favourable outcome [121]. Sequencing demonstrated 
100% concordance of HPV status. 
2.2.5 p16 staining: 
p16 staining was performed under the guidance of Philippa Jones (UCL 
Advanced Diagnostics) using the Bond™-III system, a fully-automated 
immunohistochemistry staining system (Leica Microsystems, Inc., Buffalo 
Grove, US). 3 µm sections were cut from a total of 82 FFPE blocks from 
HNSCC samples (see section 2.1.1) and were prepared for p16 staining. 
Using the Bond™-III system, slides were dewaxed using the Bond Dewax 
Solution (Leica Microsystems, Inc., Buffalo Grove, US) according to the 
manufacturer’s recommendation (protocol ‘*D’). Antigen retrieval was 
conducted using the Bond ER1 solution for 30 minutes (Leica Microsystems, 
Inc., Buffalo Grove, US) according to manufacturer’s protocol ‘*H1(30)’. 
Staining was then performed using the Bond Polymer Refine Kit and 
employing the manufacturer’s protocol ‘15,8,8’ using the pre-diluted p16 
antibody clone E6H4™ and a negative reagent control (CINtec, Ventana 
Medical Systems, Inc., US). The stained slides were examined and scored as 
described by Thavaraj et al. [122], by two experienced histopathologists. 
2.2.6 Laser-capture microdissection: 
Samples were laser-captured microdissected (LCM) to separate tumour 
epithelial from surrounding stromal tissues, enriching tumour DNA for further 
analyses. These were processed as 10 µm thick unstained slides which were 
reviewed by an expert pathologist who had marked the slides for tumour 
subtype enrichment in a corresponding H&E stained section. LCM was 
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carried out on P.A.L.M. MembraneSlide 1.0 PEN slides (Zeiss Microimaging, 
Munich, Germany) using the Zeiss Palm MicrobeamTM system. Tissue was 
collected into extraction tubes and processed using the QIAamp DNA FFPE 
Tissue Kit (Qiagen, Hilden, Germany). Extracted DNA was quantified using a 
standardized PicoGreen fluorescence assay (LifeTechnologies, Carlsbad, 
CA).  
2.2.7 Reverse transcription of extracted RNA: 
cDNA was obtained from the extracted RNA by using the SuperScript™ First-
Strand Synthesis System (Invitrogen Life Technologies, Paisley UK). 
2.2.8 E6, E7, L1 and L2 qPCR: 
Both DNA and cDNA (reverse transcribed from the extracted RNA samples) 
were used for qPCR. After having checked the accordance of the respective 
DNA and cDNA sequences with the primer sequences used, E6, E7, L1 and 
L2 qPCR and RT-qPCR were optimized using the following primers and 
TaqMan probes (and using GAPDH as a house-keeping control) to test for 
the DNA and cDNA regions of interest: 
Name of primer/probe Primer/probe Sequence (5'-3') 
HPV type 16 GAPDH forward primer 5’- GGAGTCAACGGATTTGGTCGTA -3’ 
HPV type 16 GAPDH forward primer 5’- GGCAACAATATCCACTTTACCAGAGT 
-3’ 
HPV 16 GAPDH TaqMan probe 5’-(FAM)- CGCCTGGTCACCAGGGCTGC 
-(TAMRA)-3’ 
Table 2.6: GAPDH primers and probe used for qPCR. 
Name of primer/probe Primer/probe Sequence (5'-3') 
HPV type 16 E6 forward primer 5’-TCAGGACCCACAGGAGCG-3’ 
HPV type 16 E6 reverse primer 5’-CCTCACGTCGCAGTAACTGTTG-3’ 
HPV 16 E6 TaqMan probe 5’-(FAM)-CCCAGAAAGTTACCACAGTT 
ATGCACAGAGCT-(TAMRA)-3’ 
Table 2.7: E6 primers and probe used for qPCR. 
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Name of primer/probe Primer/probe Sequence (5'-3') 
HPV type 16 E7 forward primer 5’-CCGGACAGAGCCCATTACAA-3’ 
HPV type 16 E7 reverse primer 5’-CGAATGTCTACGTGTGTGCTTTG-3’ 
HPV 16 E7 TaqMan probe 5’-(FAM)-
CGCACAACCGAAGCGTAGAGTCACACT-
(TAMRA)-3’ 
Table 2.8: E7 primers and probe used for qPCR. 
Name of primer/probe Primer/probe Sequence (5'-3') 
HPV type 16 L1 forward primer 5’- ATAATCCAGATACACAGCGGC -3’ 
HPV type 16 L1 reverse primer 5’- CCACTAATGCCCACACCTAATG -3’ 
HPV 16 L1 TaqMan probe 5’-(FAM)-
AACACCTACACAGGCCCAAACCA-
(TAMRA)-3’ 
Table 2.9: L1 primers and probe used for qPCR. 
Name of primer/probe Primer/probe Sequence (5'-3') 
HPV type 16 L2 forward primer 5’- ACGTGCATCGGCTACCCAACTTTA -3’ 
HPV type 16 L2 reverse primer 5’- ACCCGACCCTGTTCCAATTCCTAA -3’ 
HPV 16 L2 TaqMan probe 5’-(FAM)-  
AAACAGGCAGGTACATGTCCACCTGA  
-(TAMRA)-3’ 
Table 2.10: L2 primers and probe used for qPCR. 
 
DNA and cDNA were amplified using qPCR with 25 µl 2x Abgene Buffer A 
(Abgene, UK), 0.3 µM forward primer, 0.3 µM reverse primer, 0.15 µM 
TaqMan probe, in a total volume of 50 µl. Standards, a house-keeping 
control (GAPDH), and one water control sample were included in each PCR 
setup. qPCR and RT-qPCR was performed using the Eppendorf Realplex 
Mastercycler (Eppendorf, UK) applying the following qPCR programme: 
Reactions were denatured at 95°C for 15 minutes, followed by 40 cycles of 
95°C for 15 sec and 60°C for 60 sec, with no extension. All reactions were 
run in duplicate (two reactions at 1x concentrations and two reactions of 1:10 
dilutions).  
Primer efficiency for each primer set was calculated using the formula ‘[10^(-
1/-slope)]-1’, as previously described [123, 124]. Sufficient primer efficiency 
was confirmed for each primer set used (Table 2.11). Standard curves for 
each primer set used are illustrated in the Appendix Figure A.2-A.6.  
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Primers tested Slope (standard curves; 
Appendix Fig.) 
Primer efficiency 
GAPDH -3.156 107.42% 
E6 
-3.517 92.46% 
E7 
-3.3683 98.10% 
L1 
-3.2537 102.93% 
L2 
-3.264 102.48% 
Table 2.11: Calculated primer efficiencies for each primer set tested. 
Comparison of viral L1 and L2 gene expression between control states and 
5-AZA treated states of the respective cell lines was calculated using the 
delta-delta (ΔΔ) Ct method [124], according to the following formula: 
ΔΔCt = [(CtG.O.I.(treated) - CtHK.G.C.(treated)) - (CtG.O.I.(control) – CtHK.G.C.(control))] 
Genes of interest (G.O.I.): viral L1 and L2 gene. House-keeping gene control (HK.G.C): GAPDH 
A positive ΔΔCt value indicates an increase in expression of the tested gene, 
whereas a negative ΔΔCt value indicates a decrease in expression of the 
tested gene. The fold variation was calculated using the following formula: 
Fold change = 2^(-ΔΔCt) 
Standard deviation of the Delta Ct values of the tested replicates was 
estimated as the sum of squares of the standard deviations of the gene of 
interest and the housekeeping gene. This was added to, and subtracted 
from, the respective ΔΔCt values, yielding corrected ΔΔCt values. The 
obtained values were then used to calculate the corrected fold change, 
according to the following formula: 
Corrected fold change = 2^(-corrΔΔCt) 
The obtained corrected fold change value then subtracted from the fold 
change value, yielding the quantity of correction (margins of error). Mean fold 
change values were then log-transformed and plotted, with the calculated 
margins of error (error bars). Two-tailed unpaired T-tests were applied to 
determine the significance of differences between untreated and treated cell 
lines.  
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2.2.9 Gel electrophoresis: 
The electrophoretic mobility of DNA molecules is dependent on the size of a 
specific region and the concentration of agarose gel used. 2% Agarose gels 
were generally employed, although 1.5% gels were used for analysis of DNA 
fragments less than 500 bp in size, and 0.8 % gels for DNA fragments larger 
than 4 kb. The appropriate weight of agarose was added to either TBE (from 
a 10x stock of 1 litre; 108 g Tris, 55 g Boric acid,  40 ml 0.5 M Na2EDTA at 
pH 8.0, dissolved in 900 ml distilled water, or TAE buffer (40 mM Tris-
Acetate/1 mM EDTA), depending on the application and the mixture heated 
to allow the agarose to dissolve. The solution was then immediately cooled to 
approximately 60°C and ethidium bromide added to a final concentration of 1 
µg/ml. The melted agarose solution was poured into a mould with a well-
forming comb inserted and incubated at RT to allow the gel to harden. The 
DNA samples were then mixed with 6 X Gel Loading Dye Blue (New England 
Biolabs, US), loaded into the wells of the prepared gel and fragments were 
separated by electrophoresis in TBE/TAE buffer at a constant current of 270 
mA. Standard molecular weight markers (50 bp DNA  ladder and 1 kb DNA 
ladder, New England Biolabs, US) were used alongside the samples. The 
DNA was visualized and photographed under a long-wave UV light. 
 
2.3 Experimental procedures used to obtain results in 
chapter 3. 
 
2.3.1 Whole-genome methylation analysis with MeDIP-seq: 
Methylated DNA immunoprecipitation (MeDIP) was developed by Weber et 
al. in 2005 [125]. It is a whole genome DNA methylation assay that enriches 
the methylated fraction using a versatile immunocapturing approach and by 
that allows for unbiased detection of methylated DNA. This allowed me to 
interrogate approximately 70% of the host methylome and 100% of the HPV 
methylome. 
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In my experiments genomic DNA was randomly sheared by sonication (DNA 
preparation step) and the length of obtained fragments was validated using 
gel electrophoresis. The NEBNext DNA Sample Prep Mastermix (New 
England Biolabs) was then used for the library preparation step. In test runs I 
performed both manual MeDIP [126] and automated MeDIP (AutoMeDIP) 
[127]. For the analysis of fresh-frozen tumour samples AutoMeDIP was 
conducted using the IP Star (Diagenode) as previously described [127]. 
During this process the prepped DNA was immunoprecipitated with a 
monoclonal antibody that specifically recognizes 5-methylcytidine and 
subsequently the immunoprecipitated (methylated) fraction was recovered. 
Enrichment of the methylated DNA fraction (compared to input) was 
assessed using qPCR. Thereafter the methylated portion was amplified by 
adapter mediated PCR. After the adapter mediated PCR step, the library was 
subjected to size selection (300-350 bp) from low melting-point agarose gels. 
The excised fraction was quality controlled by qPCR. The work-flow is also 
illustrated in Figure 2.2.  
There are some pitfalls which should be mentioned here and which I have 
also encountered. Gel excision is a laborious and time-consuming step and a 
lot of DNA is lost in its course both during the gel excision itself and during 
the gel purification step. Thus, this has to be taken into account when 
deciding on the amount of DNA to start with in order to end up with a 
sufficient amount for cluster generation. Moreover, there is currently no 
consensus on the best methods for quantifying library concentration. 
Although I aimed to sonicate the sample DNA to have a similar size 
distribution, invariably slight variation has been observed between samples.  
MeDIP-Seq describes the combination of MeDIP with Next Generation 
sequencing. Cluster generation and 36 base paired-end sequencing was 
performed by the UCL Genomics Core Facility according to the 
manufacturer’s recommendation, using an Illumina GAIIX platform. 
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Figure 2.2: Illustrated Auto-MeDIP work-flow; e, electrophorese, p, purify, q, quantitate, 
qPCR, quantitative polymerase chain reaction (obtained from [127]). 
 
2.3.2 Data analysis of MeDIP-Seq data: 
The sequencing analysis was performed with the guidance and help of Dr. 
Gareth Wilson (Medical Genomics Group, UCL Cancer Institute). The data 
were analysed using the MeDUSA pipeline [128]. Reads were aligned to the 
reference genome (Human assembly GRCh37) using the alignment software 
BWA (v0.5.8) [129], with default parameters. Filtering was performed using 
SAMtools, (v0.1.9) [130] to remove erroneously mapped and low quality 
(score of <10) reads. Only those forming a correctly aligned pair were kept. A 
57 
 
final filtering step removed potential PCR artefacts by discarding all but one 
read-pair within groups of non-unique fragments (Table 2.12). Read quality 
was ascertained using FastQC 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) and the Bioconductor 
package MEDIPS (v1.0.0) [131]. Probes from the 450k BeadChips located 
within CpG island regions were isolated and these sites were extended to 
create 500bp windows. Absolute methylation scores for each of these 
regions were calculated from my MeDIP read files using MEDIPS. 
Methylation scores were calculated for each extended probe site using 
default values. 
Sample HPV Cycles 
Total 
Reads 
(pre-
alignment) 
Unique 
fragments 
(paired 
reads) 
Mean 
Insert 
Size 
CpG 
Enrichment 
Score 
CpG 
cover- 
age 
% 
GC 
HN_29 HPV- 36 52655678 17002647 174.43 4.06 48% 52 
HN_32 HPV- 36 58152760 19332002 189.9 3.78 54% 52 
HN_39 HPV+ 36 40889864 11829705 196.16 3.45 45% 50 
HN_96 HPV- 36 41538032 12474190 185.06 3.19 47% 49 
HN_105 HPV+ 36 36259072 11385250 173.75 3.68 44% 52 
HN_125 HPV+ 36 47522856 15101872 178.68 3.96 47% 52 
 
Table 2.12: Read counts obtained from the methylome analysis on MeDIP-Seq data.  
 
2.3.3 Genome-wide methylation analysis with Illumina 450k 
BeadChips: 
DNAs were prepared in a total volume of 20 µl (1 µg for FF and cell line 
DNAs and 2 µg for FFPE DNA per sample) using a previously optimized 
protocol [132] in conjunction with the REPLIg FFPE kit (Qiagen GmbH D-
40724 Hilden, cat No. 150243) and EZ DNA Methylation kit (Zymo Research 
Corp, Orange, CA 92867, USA, cat No. D5001). The latter was modified to 
improve bisulfite conversion efficiency by inclusion of a cyclic denaturation 
step as described previously [132]. The Infinium HumanMethylation450 
BeadChips were purchased from Illumina and processed by the UCL 
Genomics core facility according to the manufacturer’s recommendation. The 
scanned data and image output files were managed with the Genomestudio 
software (version 1.9.0) (Illumina®, Inc., San Diego, CA 92121, USA).  
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2.3.4 Data analysis of Illumina 450k BeadChips data: 
The statistical analysis was performed under the guidance, and with the 
assistance, of Dr. Andrew Teschendorff (Statistical Genomics Group, UCL 
Cancer Institute). I initially tested 3 approaches in addition to the Bayesian 
regularised T-statistics model described in detail (see below). The work-
flow/parameters used for each analysis approach are outlined in Figure 2.3. 
Using the Illumina software package ‘Genome Studio’ v1.9.0 (Illumina®, Inc., 
San Diego, CA 92121, USA), designed for the analysis of Illumina 450k 
BeadChips methylation data, 77917 MVPs were identified (adjusted P < 
0.01). Employing the Lumi pipeline [133] and an in-house method developed 
at the time of analysis, ‘Methyl-T’ (script kindly provided by P. Guilhamon, 
Medical Genomics Group, for testing), 394 MVPs and 306 MVPs were 
identified, respectively. Using a Bayesian regularised T-statistics model 
which is described in detail in the following section, 2757 MVPs were 
identified. The overlap of obtained significant MVPs is illustrated in a Venn 
diagram (Figure 2.4).  
 
Figure 2.3: Evaluation of 4 methods tested for the methylation analysis of Illumina 450k 
BeadChip data (the one chosen is highlighted in red) 
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Figure 2.4: Venn diagram based on numbers of significant methylation variable positions 
(adjusted P < 0.01) by applying the 4 different methods outlined in Figure 2.3.  
The Bayesian regularised T-statistics model was selected on the basis of its 
superior power, compared with the Methyl-T approach and the approach 
used by the Lumi package. I disregarded the results of the Genome Studio 
algorithm due to the implausibly large number of MVPs found and doubts 
over the proprietary methods employed. R statistical software v2.14.0 
(http://www.r-project.org) was used for the subsequent data analysis. Raw 
data were subjected to a stringent quality control analysis as follows: 
samples were removed which showed reduced coverage and only probes 
detected above background across all samples were kept (detection p-value 
< 0.01), resulting in a raw data matrix of 439,385 probes and 32 samples with 
18 HPV+ and 14 HPV-. This raw data matrix was then subjected to a 
principal component analysis to determine the nature of the largest 
components of variation. Random Matrix Theory was used to estimate the 
number of significant components of variation [134, 135].  
 450k BeadChips contain two types of probes (type 1 and 2) which 
have slightly different profiles. While there have been attempts to normalize 
for that difference [136], it was observed that proposed normalization 
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methods and in-house methods that were developed overcorrected the data 
leading to worse performance as evaluated using a rigorous training-test set 
partition strategy. Thus, in the supervised analysis type1 and type2 design 
probes were treated equally and tested a posteriori for a potential skew 
favouring type1 probes. Although there were only 1075 type 1 probes among 
the top 2757, this amounted to an over-enrichment with an odds ratio of 1.48 
(P < 1e - 16). However, after correcting for differences in CpG density 
between type1 and type2 probes, the enrichment odds ratio favouring type1 
probes was significantly reduced to 1.13 (P ~ 0.03). Thus, there was no 
substantial skew favouring type1 probes and it was observed that 
normalising for the design using the Peak-Based Correction method of 
Dedeurwader only led to overcorrection and increased technical variability 
(Figure 2.5). 
 
Figure 2.5: Peak-Based Correction (PBC) does not improve predictive power in FFPE 
HNSCC samples. Positive predictive value (PPV, y-axis) for the case where no design 
normalisation is performed (NDN) against PBC normalisation. The PPV is estimated in a test 
set, where features have been ranked and selected from a mutually exclusive training set. 
The boxplots are over 25 distinct training/test set choices. This shows that PBC increases 
variability within phenotypes resulting in worse performance. The PPV is estimated as the 
fraction of the selected features that have a P-value < 0.05 in the test and preserving the 
same directionality as in the training set. 
 To quantify the strength of the association and to adjust for multiple 
testing the false discovery rate (FDR) was estimated using the q-value 
procedure [137]. Since the analytical q-value estimates assume 
independence of the underlying tests, an assumption which does not 
necessarily apply to neighbouring probes that are spatially correlated, the 
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FDR was also estimated using a permutation approach which preserves the 
potential correlation structure of proximal probes. However, empirical and 
analytical FDR estimates were in close agreement (Figure 2.6). Both 
procedures estimated approximately 2750 methylation variable positions 
(MVPs) at an FDR< 0.01, i.e less than 1% of the 2757 probes are expected 
to be false positives.  
 
Figure 2.6: Close agreement of analytic and permutation-based FDR estimates. False 
discovery rate (FDR) of FFPE probes estimated by (1) red: analytic q-value procedure of 
Storey-Tibshirani and (2) black: using a permutation approach preserving the potential 
correlative structure of proximal probes (empirical). NP = number of probes, NFP = Number 
of False Positives. 
2.3.5 Copy number variation (CNV) analysis: 
CNV analysis was performed on the DNA of the three FF HPV+ and three FF 
HPV–HNSCC samples using the Illumina HumanOmni1-Quad BeadChip 
genotyping array. This analysis was required for the normalization of the 
MeDIP-seq data. CNV data were analysed using Illumina Genome Studio. 
2.3.6 Generation of SCC003 clones expressing HPV-16 oncogenes: 
Clones of SCC003 expressing either empty vector control, HPV-16 E7, HPV-
16 E6, or both HPV-16 E6 and E7, respectively, were generated by infection 
of the SCC003 cell line with retroviruses and single cell cloning as follows. 
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Viruses were produced by transfecting Human Embryonic Kidney (HEK) 
293T cells with pLXSN (empty vector or containing the HPV-16 E6, E7 or 
E6&E7 cDNAs, kind gifts from Dr. David Beach) together with pHIT- VSVG 
and MLV-gag/pol (kind gifts from Dr. Juan Martin-Serrano) using 
polyethylenimine (Polysciences, Inc.). 72 hours post-transfection, viruses 
were harvested by removal of the medium and filtration through 0.45um 
surfactant-free filters (Nalgene). The filtered virus stocks were either frozen at 
-80C or diluted 1:2 in DMEM/10%FBS containing 8ug/ml Polybrene (to give a 
final conc. of 4ug/ml) and added to SCC003 cells grown to a confluence of 
40-50%. Following overnight incubation, the cells were washed to remove 
virus and medium was replaced with DMEM/10%FBS. At 48-72hrs post-
infection cells were passaged at a ratio of 1:5 into selection medium 
containing 400ug/ml G418. Following the death of all mock-infected cells 
(approx. 1 – 2 weeks), cells were removed from selection and plated at 
limiting dilution in 96 well plates to generate single cell clones. HPV-16 E6 
and E7 qPCR were conducted as described [138, 139]. To assess E6 and E7 
expression levels in E6-transduced, E7-transduced and E6&E7-transduced 
SCC003 cell line clones (and empty vector controls), qPCR was performed 
on cDNA following reverse transcription (Superscript-II, Invitrogen) of total 
RNA purified from cells using the miRNeasy kit (QIAGEN) as per 
manufacturers’ recommendations. 
2.3.7 Survival Analysis: 
Survival Analysis on the selected 21 FFPE HPV+ and 21 FFPE HPV- 
HNSCC samples was performed using the IBM SPSS Statistics Package 
Version 20, after having retrieved the relevant clinical information. Overall 
survival was used as the outcome measure. The Log Rank test was used to 
test for significant differences and Kaplan-Meier curves plotted. 
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2.4 Methodology used and data analysis applied to 
obtain results in chapter 4 
 
2.4.1 MeDIP-Seq data analysis of the HPV genome: 
The analysis of the MeDIP-Seq data was performed with the help of Dr. 
Gareth Wilson (Medical Genomics, UCL Cancer Institute). For this the MeDIP 
sequence data from the 3 HPV+ FF HNSCC samples were used, allowing 
the interrogation of 100% of the HPV methylome. The 36 base paired-end 
sequence data were aligned to the human reference genome (Human 
assembly GRCh37) using BWA (v0.5.8) (Li and Durbin 2009), with default 
parameters. Those that failed to align to the human genome were mapped, 
using BWA, to 1776 viral genomes, including 29 human papilloma viruses 
(Table 2.13), obtained from NCBI Genomes (http://www.ncbi.nlm.nih.gov/ 
genomes/GenomesHome.cgi?taxid=10239).  
Filtering was performed using SAMtools (v0.1.9) (Li, Handsaker et al. 2009) 
to remove erroneously mapped and low quality (score of <10) reads. In order 
to compare viral aligned reads between samples, the read counts were 
normalized for viral load by dividing the number of reads in 10bp windows by 
the viral load as estimated by E6 qPCR.  Further normalization to account for 
total library size led to read counts being transformed to reads per million 
(RPM) as described in Chavez et al. 2010 [131]. 
Additionally, the MeDIP-seq data were analysed to identify potential viral 
integration sites. For this, reads that failed to form a correctly aligned pair in 
the human genome were stored. For each HPV+ sample, these stored reads 
were aligned to the HPV-16 (NC_001526) genome using BWA. Pairs in 
which one read mapped to the viral genome with an alignment score  >= 10 
and the corresponding mate failed to map, were identified (n = 182) using 
SAMtools and custom perl scripts. These reads were compared to the 
relevant human alignment to find pairs. In order to be classed as a pair, the 
human read also required an alignment score >= 10 and to have an 
unmapped mate (n = 660428). Therefore the resulting pair comprises of one 
read aligning with high confidence to HPV-16 and the other to human, 
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indicating that a potential integration site is located within the fragment 
(n=33). 
HPV type Reference Sequence 
Accession Code (NCBI) 
Human_papillomavirus_type_18_uid15506 NC_001357 
Human_papillomavirus_type_1_uid15491 NC_001356 
Human_papillomavirus_type_2_uid15512 NC_001352 
Human_papillomavirus_type_54_uid15466 NC_001676 
Human_papillomavirus_type_101_uid17121 NC_008189 
Human_papillomavirus_type_103_uid17119 NC_008188 
Human_papillomavirus_type_108_uid34847 NC_012213 
Human_papillomavirus_type_10_uid15504 NC_001576 
Human_papillomavirus_type_16_uid15505 NC_001526 
Human_papillomavirus_type_26_uid15507 NC_001583 
Human_papillomavirus_type_32_uid15508 NC_001586 
Human_papillomavirus_type_34_uid15509 NC_001587 
Human_papillomavirus_type_41_uid15485 NC_001354 
Human_papillomavirus_type_48_uid14027 NC_001690 
Human_papillomavirus_type_49_uid15455 NC_001591 
Human_papillomavirus_type_4_uid15492 NC_001457 
Human_papillomavirus_type_50_uid14327 NC_001691 
Human_papillomavirus_type_53_uid15510 NC_001593 
Human_papillomavirus_type_5_uid15511 NC_001531 
Human_papillomavirus_type_60_uid14028 NC_001693 
Human_papillomavirus_type_63_uid15486 NC_001458 
Human_papillomavirus_type_6b_uid15454 NC_001355 
Human_papillomavirus_type_7_uid15450 NC_001595 
Human_papillomavirus_type_88_uid28737 NC_010329 
Human_papillomavirus_type_90_uid15424 NC_004104 
Human_papillomavirus_type_92_uid14406 NC_004500 
Human_papillomavirus_type_96_uid15488 NC_005134 
Human_papillomavirus_type_9_uid15456 NC_001596 
 
Table 2.13: 29 human papilloma viruses, including Reference Sequence Accession Codes, 
obtained from NCBI Genomes (http://www.ncbi.nlm.nih.gov/genomes) 
To determine if there was a significant enrichment of these reads within a 
specific location on the viral genome, counts of the aligned ‘integration site’ 
reads were obtained for 500bp windows with 10bp slide. Permutation 
analysis was performed (n=10000). The probability of an ‘integration site’ 
read aligning to a specific genomic region was weighted according to the 
total number of reads aligning in that window. The resulting empirical p-
values were log transformed (-log10) and plotted along the HPV16 genome. 
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2.4.2 Validation of obtained results by bisulfite sequencing (BS-Seq): 
 
In vitro methylation of HPV+ HNSCC DNA samples: 
In vitro methylation of HPV+ HNSCC DNA samples was performed using 
CpG Methyltransferase (M.Sssi) (New England Biolabs Inc., Ipswich, US), 
according to the protocol of the supplier, in order to obtain a positive control 
for subsequent BS-Seq analysis. 
Whole-genome amplification of HPV+ HNSCC DNA samples: 
Whole-genome amplification of HPV+ HNSCC DNA samples was performed 
using the GenomePlex® Complete Whole Genome Amplification (WGA) kit 
(Sigma-Aldrich, Missouri, US) and the REPLI-g Mini Kit (QIAGEN), according 
to the protocol of the supplier, in order to obtain a negative control for 
subsequent BS-Seq analysis. 
Bisulfite modification: 
It is not possible to detect methylated cytosines by using conventional DNA 
sequencing. By applying the bisulfite conversion technique [140], methylation 
can be analysed by means of sequencing (BS-Seq). Bisulfite deaminates 
unmethylated cytosines and leads to the generation of the base uracil. 
Methylated cytosines are not converted and remain cytosines. During the 
subsequent PCR step, the modified template is amplified by PCR 
(methylated cytosines remain unchanged and unmethylated cytosines which 
are converted to uracils are amplified, leading to their replacement by 
thymines).  
One µg of genomic DNA from 3 FF HPV+ HNSCC tissue samples (analysed 
by MeDIP-Seq previously) and from 3 HPV+ HNSCC cell lines, was bisulfite 
converted using the Zymo EZ DNA Methylation kit (Zymo Research Corp, 
Orange, CA 92867, USA, cat No. D5001). The protocol was modified to 
improve bisulfite conversion efficiency by inclusion of a cyclic denaturation 
step as described previously [132]. Bisulfite conversion efficiency was 
66 
 
confirmed by methylation-specific PCR (MSP) for a methylated and 
unmethylated DNA fragment. 
Targeted HPV methylome analysis: 
In order to obtain the DNA segment of interest (the region at the boundary of 
the L1 and L2 gene within the HPV-16 genome), the targeted modified DNA 
fragment was amplified using touchdown PCR with 1x Reaction Buffer, 0.5 
mM dNTPs, 2.0-3.0 mM MgCl2, 0.4 μM of forward and reverse primers 
respectively and 1 unit of HotStar Taq (Qiagen, Crawley, UK), in a total 
volume of 20 μl (Qiagen, Crawley, UK). Reagents were denatured at 95°C for 
10 min, followed by 20 cycles of 95°C for 45 sec, 60°C with a decrease of 
half a degree per cycle for 45 sec, 68°C for 60 sec and 30 cycles of 95°C for 
45 sec, 50°C for 45 sec, 68°C for 60 sec and ending with a seven-minute 
extension at 68°C. One in vitro methylated control sample (positive control) 
and one unmethylated (whole-genome amplified) control sample (negative 
control), as well as a 50/50 mixture of both, were included in each PCR to 
ensure that methylated and unmethylated templates were both equally 
amplified, as previously described [141]. 
Initially primers were designed with BiSearch (http://bisearch.enzim.hu/) for 
the generation of a PCR product of 292 bp in length, covering the 6 CpG 
sites of interest in a region at the boundary of the L1 and L2 gene within the 
HPV-16 genome. Sequences of the initial primers are summarized in Table 
2.14. 
Name of primer Primer Sequence (5'-3') 
forward L1/2 PCR primer vol. 1 (5548-5567) AATTATTGTTGATGTAGGTG 
reverse L1/2 PCR primer vol. 1 (5819-5839) AGTTTTTAAAGTATTAGGATT 
Table 2.14: L1 and L2 PCR primers tested initially. 
The specificity of the reaction products was inspected using 1.5 % agarose 
gel electrophoresis before being purified using the Illustra ExoStar 1-Step kit 
(GE Healthcare Life Sciences, Little Chalfont, UK). 
One problem encountered was that only the methylated template was 
amplified (with primers vol. 1 used; Table 2.14). The BS-Seq trace of the 
67 
 
negative control consistently showed cytosine peaks at all 6 CpG sites of 
interest within this region, although peaks of the base thymine in the 
sequencing data at this location were expected. It was hypothesised that the 
GenomePlex® Complete Whole Genome Amplification (WGA) kit (Sigma-
Aldrich, Missouri, US) would not sufficiently amplify viral DNA and the 
experiment was repeated using the REPLI-g Mini Kit (QIAGEN). The result 
did not change following that. To check that the viral DNA was amplified as 
well as the human DNA, an E6 qPCR was run on 3 HPV+ HNSCC samples 
pre and post WGA. The delta Ct between GAPDH and E6 showed no 
difference between samples pre and post WGA, suggesting that both the 
viral and the human DNA were amplified equally well.  
Using the same PCR programme as before with a gradient of 3 temperatures 
for amplification (55°C, 60°C, 65°C), MSP primers were tested, covering 4 of 
the 6 CpG sites of interest (primer sequences obtained from [119] and 
outlined in Table 2.15), on in vitro methylated viral DNA, whole-genome 
amplified DNA and a 50/50 mixture of both, in 3 HPV+ HNSCC cell line DNA 
samples.  
Name of primer Primer Sequence (5'-3') 
M-SP F (5595-5619) TGTTACGAAAACGACGTAAACG 
M-SP R (5731-5707) CGTACAACATATTCATCCG 
UnM-SP F (5595-5619) TGTTATGAAAATGATGTAAATG 
UnM-SP R (5724-5707) CATACAACATATTCATCCA 
Table 2.15: PCR primers used for MSP. 
In contrast to the results published by Park et al. [119], amplification of both 
the methylated and unmethylated fraction, using both of these primers, was 
found, not allowing the validation of the methylation status within this region. 
PCR primers used for BS-Seq by Park et al., were then tested, covering the 6 
CpG sites of interest in a region at the boundary of the L1 and L2 gene within 
the HPV-16 genome, in order to validate my viral methylome analysis 
employing MeDIP-Seq. Sequences of these primers are summarized in 
Table 2.16. A product of 421 bp (see Figure 2.7) was generated by PCR 
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using the PCR programme outlined above and purified using the Illustra 
ExoStar 1-Step kit (GE Healthcare Life Sciences, Little Chalfont, UK). 
Name of primer Primer Sequence (5'-3') 
forward L1/2 PCR primer vol. 2 (5541-5569) AATATATAATTATTGTTGATGTAGGTGAT 
reverse L1/2 PCR primer vol. 2 (5984-5962) ACCCACACCTAATAACTAACCAC 
Table 2.16: L1 and L2 PCR primers used for validation of MeDIP-Seq results by BS-Seq. 
     5521 tatagttcca gggtctccac aatatacaat tattgctgat gcaggtgact tttatttaca 
     5581 tcctagttat tacatgttac gaaaacgacg taaacgttta ccatattttt tttcagatgt 
     5641 ctctttggct gcctagtgag gccactgtct acttgcctcc tgtcccagta tctaaggttg 
     5701 taagcacgga tgaatatgtt gcacgcacaa acatatatta tcatgcagga acatccagac 
     5761 tacttgcagt tggacatccc tattttccta ttaaaaaacc taacaataac aaaatattag 
     5821 ttcctaaagt atcaggatta caatacaggg tatttagaat acatttacct gaccccaata 
     5881 agtttggttt tcctgacacc tcattttata atccagatac acagcggctg gtttgggcct 
     5941 gtgtaggtgt tgaggtaggc cgtggtcagc cattaggtgt gggcattagt ggccatcctt 
Figure 2.7: 421 bp viral DNA segment of interest. 
 
Bisulfite sequencing: 
 
Methylation analysis was performed with bisulfite genomic sequencing using 
the bisulfite modified and PCR amplified and purified DNA segment of 
interest (421 bp segment at the border of the L1 and L2 gene in the HPV-16 
genome, harbouring the 6 CpG sites of interest in genomic positions 5600, 
5606, 5609, 5615, 5707, and 5724 (and two additional CpG sites). The same 
primers (Table 2.16) were used for BS-Seq.  
It ought to be mentioned that, after bisulphite treatment and PCR 
amplification, a subcloning step is frequently included before sequencing. 
This is done to avoid a molecular weight shift, detected during the 
sequencing reaction, when CpG rich regions are analysed. This shift is a 
result of the analysis of a mixture of methylated (+ CH3) and unmethylated (- 
CH3) CpG sites within the segment of interest in a heterogeneous DNA 
population. However, in my case, the segment of interest only contained 8 
CpG sites (within a 421 bp viral DNA segment). Thus, no significant 
molecular weight shift was expected. In order to cause a molecular weight 
shift of one base, the DNA segment would have to contain 22 CpG sites 
which are differentially methylated in a cell population. Hence, a subcloning 
step was not included. Although Sanger sequencing is not a quantitative 
method, looking at the results obtained from the positive (in vitro methylated) 
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and negative (whole-genome amplified) control, one can be confident that it 
is a good indicator of methylation of this locus in the HPV type 16 genome. 
BS-Seq was performed by the UCL Genomics Core Facility according to the 
manufacturer’s recommendation using Applied Biosystems Bigdye3.1 
chemistry. Sequencing reactions were cleaned up using in-house-made 
sephadex filtration plates and then run on Applied Biosystems 3730XL 
Genetic Analyser. 
2.4.3 5-AZA treatment of cell lines: 
Three HPV+ HNSCC cell lines (UPCI:SCC90, UM:SCC47, 93VU-147T) were 
plated in 6-well plates (1.5 x 10 cells/well) with 1 ml of culture medium and 
incubated with increasing amounts of 5-Aza-2'-deoxycytidine 98+% (5-AZA; 
Fisher Scientific, Pittsburgh, US), dissolved in phosphate-buffered saline 
(PBS), for 72 hours. Culture medium was changed every 24 hours and 
freshly prepared 5-AZA was added. Concentrations of 5-AZA (1 µM, 2 µM, 5 
µM and 10 µM) used were chosen according to available literature, 
describing the treatment of HNSCC cell lines [142, 143], cervical cancer cell 
lines [144, 145], and cell lines from other cancers, such as colorectal cancer 
[146] with 5-AZA.   
 
2.5 Methodology used and data analysis applied to 
obtain results in chapter 5. 
2.5.1 Exon-sequencing of 182 genes often mutated in cancer: 
Paired-end sequencing of hybrid-captured DNA, targeting 3,230 exons in 182 
cancer-related genes plus 37 introns from 14 genes often rearranged in 
cancer was done in collaboration with Foundation Medicine (Cambridge, MA, 
US). These genes are known to be somatically altered in human solid 
cancers based on recent scientific and clinical literature. 
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DNA Library Construction and Hybrid Capture   
Molecular barcode-indexed ligation-based sequencing libraries were 
constructed using 50-200ng of total genomic DNA recovered from the 
sample. Libraries were hybridization captured with custom biotinylated RNA 
oligo pools (custom SureSelect kit, Agilent) representing 3,230 exons in 182 
cancer-related genes (most commonly altered in cancer, from 
http://www.sanger.ac.uk/genetics/CGP/cosmic/) plus 37 introns from 14 
genes often rearranged in cancer (Appendix Table A.1).  
Sequencing and Analysis  
Paired end sequencing (49 x 49 cycles) was performed using the HiSeq2000 
(Illumina). Sequence data from gDNA, available from 18 HPV+ and 16 HPV- 
samples, were mapped to the reference human genome (human assembly 
GRCh37) using the BWA aligner [129] and processed using publicly available 
SAMtools [130], Picard (http://picard.sourceforge.net) and GATK [147].  
Genomic base substitutions and indels were detected using custom tools 
optimised for mutation calling in heterogeneous tumour samples, based on 
statistical modelling of sequence quality scores and local sequence 
assembly. Variations were filtered using dbSNP_135_ENREF_1 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and a custom artifact database, 
then annotated for known and likely somatic mutations using COSMIC [148].  
Copy number alterations were detected by comparing targeted genomic DNA 
sequence coverage with a process-matched normal control sample. Genomic 
rearrangements were detected by clustering chimeric reads mapping to 
targeted introns. 
2.5.2 Validation of selected mutations by Sequenom OncoCarta: 
DNA extracted from FFPE samples were sent to Sequenom (Hamburg, 
Germany) for blind testing and analysis, using Sequenom OncoCarta panels 
v1.0 and v3.0, as previously described [149]. In brief, the Sequenom 
OncoCarta Panel™ represents a high-throughput panel for somatic mutation 
profiling [150], combining PCR and Matrix Assisted Laser Desorption 
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Ionization Time Of Flight Mass Spectrometry (MALDI-TOF MS). Mutations 
covered by panel v1.0 and v3.0 are outlined in Appendix Table A.2. 
2.5.3 Confirmation of copy number changes by Infinium CNV 
Profiling: 
Data analysis was performed under the guidance of Dr. Andrew Feber 
(Medical Genomics, UCL Cancer Institute). CNA data was generated from 
un-normalised signal intensities from the methylation data from HPV+ and 
HPV- HNSCC. Signal intensities were extracted for each sample using 
Genome Studio. Intensities were subsequently quantile normalised and a 
log2 ratio to normal reference DNA generated. Intensities from Type I and 
Type II probes were normalised independently as well as in combination. GC 
content normalisation was carried out using loess (Marioni et al., 2007). 
Circular Binary Segmentation (CBS), from the R package DNAcopy, was 
then performed to define chromosomal segments with differing copy number 
states. Thresholds for the identification of single copy CNAs were derived 
from the difference in log ratio between normal reference DNA from male and 
female samples (cut-off +/- 0.33) denoting a single copy change in the X 
chromosome, high-level amplifications and homozygous deletions were 
defined incrementally from this threshold.  
2.5.4 Validation of exon-sequencing data by Immunohistochemistry 
and interpretation of results:   
Immunohistochemistry was done in collaboration with UCL Advanced 
Diagnostics. All sequenced HNSCC samples were stained for PTEN and for 
Cyclin D1 using the Bond™-III system (Leica Microsystems, Inc., Buffalo 
Grove, US) according to the manufacturer’s recommendation, as described 
in section 2.2.5. Antibody 04-409 (Millipore-Merck KGaA, Darmstadt, 
Germany) was used for PTEN staining and antibody P2D11F11 (Novocastra) 
was used for Cyclin D1 staining of 3 µm thick sections. For antigen retrieval 
method and primary antibody dilution please refer to Table 2.17. The stained 
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slides were examined and scored as previously described [151, 152], by two 
experienced histopathologists.  
 Antibody dilution Antigen retrieval method 
CCND1 1:20 Bond solution ‘ER2’ for 30 minutes 
PTEN 1:200 Bond solution ‘ER2’ for 20 minutes 
Table 2.17: Antigen retrieval method and primary antibody dilution for CCND1 and PTEN 
staining. 
2.5.5 Survival Analysis: 
R statistical software v2.14.0 (http://www.r-project.org) was used for survival 
analysis of 9 HNSCC patients with a CCND1 amplification in their tumour 
tissue (detected by next generation sequencing; see method section 2.5.1) 
and 25 HNSCC patients who did not harbour a CCND1 amplification within 
their tumours. A Cox regression model (proportional hazard model) was fitted 
with a single CCND1 predictor (after having removed non-significant factors). 
A log rank test was performed and Kaplan-Meier curves were plotted. 
 
2.6 Methodology used and data analysis applied to 
obtain results in chapter 6 
2.6.1 Multi-dimensional scaling (MDS; principal coordinates analysis): 
R statistical software v2.15.1 (http://www.r-project.org) was used for pre-
processing of data and for classical multi-dimensional scaling (MDS) 
(principal coordinates analysis). MDS was used to visualise HPV+ and HPV- 
HNSCC methylation signatures within methylation datasets obtained from an 
HPV-induced cancer type (cervical cancer) and an smoking-induced cancer 
type (lung cancer). 
The following Illumina Infinium 27k BeadChip datasets were identified on the 
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/), a public 
functional genomics data repository: 
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 ‘GSE32861 : Genome-scale analysis of DNA methylation in lung 
adenocarcinoma and integration with mRNA expression [Homo 
sapiens]’ from [153] 
 ‘GSE30759: Epigenome analysis of normal and cancer tissue from 
the uterine cervix [Homo sapiens]’ from [154] 
The respected datasets were downloaded and data matrices were extracted. 
Phenotype information was checked and the relevant methylation data (beta 
values) were extracted for cancer samples only (data on normal 
tissue/adjacent tissue were removed).  
In detail, for the lung cancer dataset 27578 probe IDs of 59 lung cancer 
samples (of a total of 118 with 59 lung cancer and 59 adjacent tissue 
samples) were selected. For the cervical cancer dataset, 27578 probe IDs of 
48 cervical cancer samples (of 63 samples in total) were selected.  
The relevant methylation data from my own processed dataset of 18 HPV+ 
and 14 HPV- HNSCCs were extracted. 439385 probe IDs of 32 HNSCC, 18 
HPV+ and 14 HPV- samples, respectively, were used for further filtering. 
Having ensured the same ordering of respective probe IDs, NA’s  were 
removed, culminating in data matrices of 27300 probe IDs (59 lung cancer 
samples), 26871 probe IDs (48 cervical cancer samples), 439385 probe IDs 
(18 HPV+ HNSCC samples), and 439385 probe IDs (14 HPV- HNSCC 
samples). All the datasets were restricted to the common probe IDs (24145 
probe IDs), by the ‘intersect’ function, resulting in the following datasets: 
 beta values from intersected 24145 CpGs from 48 cervical cancer 
samples 
 beta values from intersected 24145 CpGs from 59 lung cancer 
samples 
 beta values from intersected 24145 CpGs from 18 HPV+ HNSCC 
samples 
 beta values from intersected 24145 CpGs from 14 HPV- HNSCC 
samples 
These were then used for multi-dimensional analysis.  
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In detail, the previously obtained methylation differences identified by 
comparing HPV+ with HPV- HNSCC samples served as a starting point, a 
semi-supervised selection of HPV-associated vs. smoking associated 
features. As outlined in chapter 3, 2757 MVPs were identified (using a 
Bayesian regularised t-statistics model) with a false discovery rate < 0.01 in 
HPV+ HNSCC, compared with HPV- HNSCC. The respective probe IDs were 
intersected with the common probe IDs identified in each dataset (lung 
cancer, cervical cancer, HPV+ HNSCC, HPV- HNSCC) using the ‘intersect’ 
function in R. This resulted in 90 common probe IDs identified across all the 
datasets. 
In order to check whether I observe the same pattern in cervical cancer vs. 
lung cancer, a multidimensional scaling of the samples was created using a 
Euclidean distance measure after scaling all common probe ID features, with 
the R ‘cmdscale’ function. A Wilcoxon rank sum test was employed to test 
intersample distances between the evaluated datasets (the set of distances 
between HPV+ HNSCC and cervical cancer samples was compared with the 
set of distances between HPV+ HNSCC and lung cancer samples). 
Distances were graphically illustrated using the ‘ggplot2’ function. 
2.6.2 Hierarchical clustering: 
In order to obtain the presented results in chapter 6 (section 6.1.5), R 
statistical software v2.15.1 (http://www.r-project.org) was used and the 
‘hclust’ function (http://svn.r-project.org/R/trunk/src/library/stats/R/hclust.R) 
was applied to perform hierarchical clustering (Euclidean distance, complete 
linkage) of HPV+ and HPV- HNSCC samples, using panels of genetic 
(chapter 5) and epigenetic candidate markers (chapter 3). 4 samples had to 
be removed as for these only methylation data, but no mutation data were 
available or vice versa (P40_neg, P70_neg, P95_neg, and P105_pos). A cut-
off of a beta value of 0.5 was used to define a CpG site as either methylated 
(1) or unmethylated (0) for the purpose of the clustering.  
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3. Chapter 3: Host Methylome Analysis of HPV+ 
and HPV- HNSCC 
 
Chapter 3 
 
Host Methylome Analysis of HPV+ and HPV- 
HNSCC 
 
The following chapter evaluates changes in the host methylome of 
HPV+ HNSCC, compared with HPV- HNSCC. I test my hypothesis that HPV 
modulates the epigenome in HNSCC by comprehensive methylome analysis 
of HPV+ and HPV- primary tumours and cell lines. In this chapter the results 
of my experiment are outlined, aiming to phenocopy the observed HPV-
mediated DNA methylation signature by ectopic expression of HPV 
oncogenes in HPV- HNSCC cell lines. 
 
3.1 Results. 
 
3.1.1 Patient demographic data: 
The median age is similar, but slightly higher in the HPV- group (58.4 vs. 
56.9 years) (Table 2.3). Male to female ratio is similar between the groups, 
and the majority of cases show moderately or poorly differentiated histology 
with evidence of lymph nodal involvement at presentation. In the evaluated 
cohort, as predicted, the vast majority of HPV- cases are amongst active 
smokers and/or heavy alcohol users. The survival analysis which I performed 
on these 21 HPV+ and 21 HPV- samples, showed that the overall survival, is 
significantly higher (P = 0.036; Log Rank test) in patients who have HPV+ 
HNSCC, compared with those who have HPV- HNSCC (Figure 3.1).  
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Figure 3.1: Survival analysis on the 21 HPV+ and 21 HPV- samples, selected for 
methylation analysis, showing that the overall survival is significantly higher in patients who 
have HPV+ HNSCC, compared with those who have HPV- HNSCC (P = 0.036; Log Rank 
test). One patient died of a stroke 3 days after the diagnosis with HPV+ HNSCC and this 
explains the initial drop of the Kaplan-Meier curve of the HPV+ HNSCC patient group. 
 
3.1.2 HPV+ tumours have a distinct DNA methylation signature: 
To investigate whether HPV+ and HPV– tumours have distinct epigenetic 
signatures, genome-wide DNA methylation profiling was performed using the 
450k Illumina Infinium platform [83], which allows the methylation state of 
over 480,000 cytosine sites (mostly CpG sites) to be interrogated. Formalin 
Fixed Paraffin Embedded (FFPE) samples from 21 HPV+ and 21 HPV– 
tumours were analysed. Raw data were subjected to a stringent quality 
control analysis (Methods). This resulted in a raw data matrix of 439,385 
probes and 32 samples (18 HPV+ and 14 HPV–). This raw data matrix was 
then subjected to a principal component analysis (PCA) to determine the 
nature of the largest components of variation. Using Random Matrix Theory 
(RMT) [134, 135] it was estimated that a total of 9 significant components of 
variation which were mainly correlated with biological factors. The first two 
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components correlated with HPV status (Figure 3.2) and confirming this, a 
scatterplot along these showed that samples segregated according to HPV 
status (Figure 3.3). 
 
Figure 3.2: Singular value decomposition: PC-k denotes the kth principal component, DA 
denotes survival at censoring date. The first two principal components PC-1 and PC-2 most 
strongly correlate with HPV status, whilst the remaining significant components associate to 
clinical parameters including alcohol consumption, smoking, age, sex, tumour stage and 
grade. No association was found with technical factors (such as Sentrix position and Sentrix 
ID) on the array. 
 
Figure 3.3: Singular value decomposition: The first two principal components clearly 
distinguish HPV status: m/f indicates male/female, HPV+ samples are plotted in black, HPV– 
samples are in red. 
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Figure 3.4: Unsupervised analysis of the top 250 MVPs in FFPE HPV+ and HPV- tumour 
samples. 
Clusters inferred by the unsupervised consensus clustering algorithm for the top 250 
methylation variable positions (MVPs) as found using the median absolute deviation (MAD) 
estimator. 
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Importantly, there was no substantial variation associated with technical 
factors including Sentrix position/Sentrix ID (Figure 3.2). Since the first two 
principal components of these data corresponded most strongly with HPV 
status, it was naturally expected that unsupervised clustering over the most 
variable probes would result in segregation of samples according to HPV 
status. As defined previously [155], such probes or CpG sites are referred to 
as Methylation Variable Positions (MVPs) and as hyper- or hypo-MVPs when 
directionality towards differential hyper- or hypomethylation has been 
ascertained. Segregation was confirmed by consensus clustering over the 
top 250 MVPs (Figure 3.4).  
Next, a supervised analysis was performed in order to ascertain the 
association between DNA methylation and HPV status. To rank probes, a 
Bayesian regularised t-statistics model [156] was used, which has been used 
and validated in the context of DNA methylation data [157]. Consistent with 
the previous unsupervised analysis, a histogram of P-values from the 
supervised analysis showed a clear trend towards small significant P-values 
(Figure 3.5). 
 
Figure 3.5: Histogram of P-values from the supervised analysis showed a clear trend 
towards small significant P-values 
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Using two alternative procedures (q-values [137] and a permutation approach 
(Methods), 2757 MVPs were found with a false discovery rate < 0.01, i.e. 
less than 1% of the 2757 MVPs are expected to be false positives. Of these 
2757 MVPs, the overwhelming majority (2408, 87%) were hyper-MVPs in 
HPV+ samples compared with HPV–, indicating that HPV infection is 
associated with widespread gain of DNA methylation. The MVPs indicating 
differential methylation between HPV+ and HPV– samples did so 
independently of gender. Indeed, a ranked set of MVPs associated with HPV 
status for the 24 males and 8 females were derived separately and the 
resulting statistics were highly correlated (Figure 3.6). 
 
Figure 3.6: Independence of HPV status and gender: scatterplot of t-statistics of individual 
CpGs reflecting HPV status (positive t-statistics indicate hypermethylation in HPV infected 
samples). P-value computed using Wilcox rank sum test. 
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Figure 3.7: Methlyation status according to gene feature annotation, showing a clear trend 
towards hypermethylation (P= 0.017). Gene features: TSS1500, TSS200, 5’UTR, 1st exon, 
gene body, 3’UTR. 
 
To investigate if the directional DNA methylation changes were related to the 
position of the MVPs relative to the corresponding genes, each MVP was first 
categorised into one of 6 gene feature groups (TSS1500, TSS200, 5’UTR, 
1stExon, Body, 3’UTR). Hyper-MVPs in HPV+ samples were preferentially 
located upstream or near the TSS or in gene bodies but not in 1st exons, 
while hypo-MVPs in HPV+ samples were preferentially located in gene 
bodies (Figure 3.7). Taken together, these data clearly show that the HPV+ 
tumour samples have a distinct epigenetic signature which shows a 
significant skew towards hypermethylation (Figure 3.7). 
3.1.3 HPV+ HNSCC are heterogeneous with a candidate CpG Island 
Methylator Phenotype (CIMP)  
The enrichment of hyper-MVPs in HPV+ samples and the observation that 
many of these mapped to CpG islands suggested a possible association with 
CIMP in these samples. To investigate this further consensus clustering over 
the top 1000 MVPs was performed, a procedure similar to the one used 
previously to discover CIMP phenotypes in breast and brain cancer [158, 
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159]. The consensus clustering yielded 4 clusters, which still correlated with 
HPV status, but also revealed heterogeneity within the HPV+ and HPV- 
subtypes (Figure 3.8). Specifically, it was observed two main subgroups of 
HPV+ samples, with subtype 1a exhibiting higher methylation levels (Figure 
3.8). This subtype was also characterised by higher average methylation 
levels when the MVPs were restricted to CpG islands (Figure 3.9), 
suggestive of CIMP. However, and in contrast to the CIMPs reported in 
breast, colon and brain cancer, there was no evidence of a stronger 
correlated hypermethylation pattern in this subtype than in the rest of HPV+ 
tumours. Interestingly, the samples in my candidate CIMP cluster 1a were all 
of poor outcome, exhibiting significantly shorter survival times compared with 
1b which contained mostly good outcome patients (Log-rank P = 0.001, 
Figure 3.9; also Figure 3.8).  
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Figure 3.8: Unsupervised analysis of the top 1000 MVPs in FFPE HPV+ and HPV- tumour 
samples:  
A) Consensus clustering identifies four sub-groups in HPV+ and HPV- groups, revealing 
sub-group 1a as candidate CIMP within the HPV+ group. 
B) Clusters inferred by the unsupervised consensus clustering algorithm for the top 1000 
MVPs as found using the MAD estimator. 
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Figure 3.9: Testing for the presence of a HPV+ CIMP phenotype. 
A) Distribution of mean methlyation values across the top 1000 MVPs in HPV+. As 
illustrated, there was a slight bimodality (coefficient of bimodality = 0.6, for which 0.555 ~ 
uniform and 1 ~ Bernoulli) in the distribution of mean methlyation values across the top 1000 
MVPs in HPV+, with significant hypermethylation of the CIMP+ cluster (1a, light green). 
Across all probes, no multimodality was observed, nor any significant separation of mean 
methylation levels between the CIMP+ cluster and the large HPV+ positive cluster with lower 
methylation levels (1b, dark green). All points of the distribution are displayed below the 
histograms (black) and density plots (grey).  
B) Significant separation (one sided P = 0.015) of between-sample correlation distributions 
of the CIMP+ cluster (1a) and cluster 1b.  
C) Association of mean methylation levels with survival independent of HPV status. There 
was an anticorrelation between mean levels across the top 1000 MVPs and survival time. 
Comparing the overall survival of patients in the CIMP+ cluster (1a) with patients in HPV+ 
cluster 1b, the HPV+ CIMP+ patients showed a significantly worse outcome (Log-rank P = 
0.001). 
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3.1.4 Validation of the hypermethylation signature in HPV+ tumours 
To validate these findings, I performed 450k Infinium profiling on 6 
independent fresh frozen (FF) samples (3 HPV+ and 3 HPV–). All 6 samples 
passed the quality control criteria (Methods). The same Bayesian supervised 
analysis was applied to rank MVPs according to how well they discriminated 
the 3 HPV+ from the 3 HPV– samples. The overwhelming majority of MVPs 
that were significantly hypermethylated in HPV+ FFPE samples were also 
hypermethylated (and many significantly hypermethylated) in the HPV+ FF 
samples relative to HPV– samples. Comparing the regularized t-statistics 
obtained from the 32 FFPE samples with those obtained from the 6 FF 
samples, a very strong agreement was observed (Wilcox P = 3e-35; Figure 
3.10A). A control set of probes which did not differ between HPV+ and HPV– 
FFPE samples, also did not correlate with HPV status in the FF set (Figure 
3.10B). 
 
To further validate these findings and the 450k technology, the 450k 
methylation values for CpG islands to methylation scores calculated from 
MeDIP-seq using the MEDIPS package was compared, testing the 3 HPV+ 
FF and 3 HPV– FF samples. A strong agreement between the two methods 
was observed (Figure 3.11).   
 
Next, it was asked if the DNA methylation changes associated with HPV 
status were also present in HPV infected HNSCC cell lines. HPV t-statistics 
between the FFPE and HPV cell line experiments correlated strongly (Wilcox 
P = 2e-27, Fig. 3.10c). Changes in absolute mean beta value (Δβ) observed  
between HPV+ and HPV– cell lines were substantially larger in contrast to 
the changes detected in FFPE (Paired Wilcox P = 7e-15) and again larger 
than in FF tumour samples (Paired Wilcox P = 3e-13, Figure 3.12).  
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Figure 3.10: Validation of HPV+ and HPV- methylation signature. 
A-C) Validation of consistency of t-statistics between FFPE and (A) FF samples, (B) FF 
control probes and (C) HPV+ against HPV- cell lines. 
D) Heatmap representation of signature of consistent hyper-MVPs (top) and hypo-MVPs 
(bottom) in Infinium DNA methylation data. The DNA methylation (beta) values are 
represented using a colour scale from yellow (low DNA methylation) to blue (high DNA 
methylation) normalized across each MVP. The HPV+ HNSCC methylation signature 
contains 2194 consistent hyper-MVPs and 74 consistent hypo-MVPs across all three 
datasets. 
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Figure 3.11: Validation of the 450k technology by MeDIP-Seq. Methylation score calculated 
from MeDIP-Seq using the MEDIPS package (MEDIPS Score) and beta values for CpG 
islands (Beta Score), testing the 3 HPV+ FF and 3 HPV– FF samples. Correlation 
coefficients (Pearson) illustrated above each scatterplot. 
 
 
 
Figure 3.12: Comparison of methylation differences across all datasets. Boxplots of changes 
in absolute mean beta value (Δβ) of the top 1000 MVPs in HPV+ and HPV– cell lines, FFPE 
tumours and FF tumours. Methylation changes are substantially larger in cell lines in contrast 
to the changes detected in FFPE (Paired Wilcox P = 7e-15) and again larger than in FF 
tumour samples (Paired Wilcox P = 3e-13). 
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In conclusion, we identified 2194 consistent hyper-MVPs and 74 consistent 
hypo-MVPs across all three experiments (FFPE HNSCCs, FF HNSCCs and 
HNSCC cell lines, as illustrated in Figure 3.10D). This confirms that my 
HPV+ hypermethylation signature obtained from FFPE samples validates in 
an independent set of HNSCC samples as well as in HPV+ HNSCC cell lines 
and indicates a strong association of the observed methylation signature and 
HPV status. 
3.1.5 Ectopic expression of HPV-16 oncogene E6 partially 
phenocopies the hypermethylation signature: 
In order to functionally validate my obtained HPV+ hypermethylation 
signature, I infected an HPV– HNSCC cell line with retroviral vectors 
containing either or both HPV-16 oncogenes, E6 and E7. After confirmation 
of ectopic expression of these HPV oncogenes in 3 clones of each cell line 
(Table 3.1), I performed DNA methylation profiling on E6, E6&E7 and E7 
infected clones relative to empty vector controls. 
The skew towards hypermethylation (observed in the described experiment 
on FFPE HNSCCs) was confirmed to be highly significant in E6 and E6&E7 
infected clones against the background probability of hypermethylation (there 
was widespread hypermethylation in E6 and E6&E7 clones) (Figure 3.13, 
Monte Carlo, P = 0.007).  
The distribution of methylation changes in E6, E6&E7 and E7 infected clones 
compared with controls is illustrated in Figure 3.14. 
 
In contrast to E6 and E6&E7, E7 was shown not to contribute to this 
hypermethylation signature (comparison of clones infected with E7 compared 
with controls; one-sided Wilcox P = 1). The skew towards hypermethylation 
was significantly larger for E6 than for E6&E7. This is consistent with the 
lower expression levels of E6 in E6&E7 co-infected clones compared with E6 
infected clones (Table 3.1). The results of the entire experiment are 
summarized in two graphs (Figure 3.13 A, B). In conclusion, ectopic 
expression of E6 in HPV– HNSCC cell line clones partially phenocopies the 
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hypermethylation signature observed in HPV+ HNSCC tumours. However, 
no final conclusion can be drawn, as E7 expression was detected at lower 
levels in infected cell lines, compared with those of E6 (Table 3.1). 
 
  
Normalized* E6 
expression levels 
Normalized* E7 
expression levels 
pLXSN-E6 clone 4 0.43 0.00 
pLXSN-E6 clone 1 0.25 0.00 
pLXSN-E6 clone 2 0.11 0.00 
pLXSN-0 clone 2  0.00 0.00 
pLXSN-0 clone 3  0.00 0.00 
pLXSN-0 clone 4  0.00 0.00 
pLXSN-E6/E7 clone 1  0.01 0.11 
pLXSN-E6/E7 clone 2  0.01 0.06 
pLXSN-E6/E7 clone 5  0.01 0.06 
pLXSN-E7 clone 2  0.00 0.09 
pLXSN-E7 clone 4  0.00 0.02 
pLXSN-E7 clone 5  0.00 0.07 
*Normalized to UPCI:SCC90 
 
Table 3.1: Normalized expression levels of the viral oncogenes E6 and E7 in infected cell 
line clones with graphical illustration (bar chart).  
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Figure 3.13:  Validation of consistent hyper-MVPs in E6 and E6&E7 infected cell line clones. 
A) FFPE hyper-MVP signature consistent with E6 (E6 only and E6&E7 infected) vs. empty 
vector controls (Monte Carlo P= 0.007). The volcano plot shows t-statistics of E6 vs. empty 
clones plotted against log10 FFPE P-values. 
B) Heatmap representation of consistent hyper-MVPs in E6, E6&E7, E7 infected clones and 
empty vector controls. Yellow indicates relative hypomethylation in HPV+ samples whilst 
blue indicates hypermethylation (MVPs normalized across samples). 
 
 
Figure 3.14: Scatterplots of change in mean methylation change Δβ (y-axis) against 
hypermethylated probes in FFPE samples (x-axis). A one-sided Wilcox test of top 1000 
FFPE probes (annotating across all datasets) illustrating that the hypermethylation signature 
observed in FFPE is partially recapitulated by E6 infected and E6&E7 infected clones. The 
mean of the distribution is marked with a horizontal and the total number of probes in each 
class is annotated in the appropriate colour (hypomethylated: orange; hypermethylated: 
blue). 
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3.1.6 Enrichment of PRC2 targets, especially members of the 
Cadherin superfamily within the hypermethylation signature: 
To find consistent targets across all the data sets (FFPEs, FFs and HPV+ 
cell lines), all of the consistent hyper- and hypo-MVPs identified above to 
genes were assigned and a Gene Set Enrichment Analysis (GSEA) was 
conducted. The hyper-MVPs which make up the majority (96.7 %) of MVPs 
identified several SUZ12 and PRC2 targets (Appendix Table A.3: Gene set 
enrichment analysis on consistent hyper-MVPs) including multiple members 
of the Cadherin superfamily. Indeed, there was significant (11 probes total, 
Fisher P = 4e-7) enrichment of hyper-MVPs within the Cadherin genes. This 
was also the case in the top 1000 MVPs (Fisher P = 0.0003). The possible 
biological impact of these Cadherins was tested in three separate ways: (1) 
by showing that their methylation states were sufficient to accurately cluster 
samples according to HPV status, (2) by showing that they have consistent 
and significant hypermethylation across their promoter regions (see DMR 
section) and (3) by showing that this promoter hypermethylation associates 
with decreased gene expression in existing data (see expression section). 
Using the k-medoids clustering algorithm (pam in the R package survival), 
the 11 cadherin-annotated probes within the top 1000 MVPs were found to 
be sufficient to detect HPV status (84% correctly classified; 27/32). These 11 
MVPs mapped to CpG islands, shores or shelves of 6 Cadherin genes 
(CDH8, CDH15, PCDH8, PCDH9, PCDH10 and PCDHB3). The remaining 
3.3% hypo-MVPs were enriched for two gene sets previously shown to 
display upregulation of gene expression in HPV+ head and neck cancers [20, 
22]. Among the top 100 hits consistent enrichment of genes involved in DNA 
replication and binding, the MAPK pathway and E2F-targets was also found 
(Appendix Table A.4: Gene set enrichment analysis on consistent hypo-
MVPs). 
To assess the MVP associations in a more biologically relevant context, they 
were grouped into differentially methylated regions (DMRs) if at least 3 
(range 3-7) had correlated differential methylation levels within the TSS200 
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promoter region. TSS200 was chosen because it was the most significantly 
positively (P = 2.4e-5) enriched category of the 6 tested (Figure 3.15).  
 
Figure 3.15: Enrichment (%) of hypermethylation of promoter regions amongst MVPs. 
Significant over-representation of the TSS200 (35%), 1stExon (23%) and 5’UTR (18%) 
regions amongst the top 1000 MVPs (P < 0.05 in each case) and significant under-
representation in the Body (–28%) and 3’UTR (–42%) 
Applying this filter, the 2194 consistent hyper-MVPs mapped to 906 distinct 
genes such that 416 had at least three probes in their respective TSS200 
regions. Of these 416 genes, 43 hypermethylated TSS200 DMRs (delta beta 
> 0.1) were derived across FFPE HNSCCs, FF, HNSCCs and HNSCC cell 
lines. A sample permutation approach yielded an expected 4.4 false positives 
(Methods). HPV cell lines showed the largest changes in mean TSS200 
hypermethylation, significantly larger than FFPE (Paired Wilcox P = 5e-05) 
which showed significant hypermethylation relative to FF (Paired Wilcox P = 
1e-06, Figure 3.16).  
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Figure 3.16: Comparison of methylation differences across all datasets. Boxplots of changes 
in mean beta value (Δβ) of promoter DMRs in HPV+ and HPV– cell lines, FFPE tumours and 
FF tumours. HPV cell lines showed the largest changes in TSS200 methylation, significantly 
larger than FFPE (Paired Wilcox P = 5e-05) which showed significantly higher methylation 
relative to FF (Paired Wilcox P = 1e-06). 
Using the same approach for the 74 consistent hypo-MVPs, 5 
hypomethylated TSS200 DMRs were derived. Figure 3.17 shows exemplar 
profiles of a hyper-DMR for CDH8 and a hypo-DMR for MEI1.   
 
Figure 3.17: Exemplar profiles of a hyper-DMR for CDH8 and a hypo-DMR for MEI1.  
Comparison of DMR profiles obtained from FFPE HNSCCs, FF HNSCCs and HNSCC cell 
lines. The profiles clearly show the increasing power to detect MVPs and DMRs dependent 
on cell type purity (cell line > laser capture microdissected FFPE > FF). Feature annotation is 
as provided by BeadChip and methylation values are colour-coded accordingly: TSS1500 = 
orange (1500 bp to 200 bp upstream of the transcription start site), TSS200 = red (200 bp 
upstream of the transcription start site), 5’UTR = yellow, gene body = blue, CpG islands = 
black, CpG shores = grey and CpG shelves = light grey.  
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These profiles highlight the increasing power to detect MVPs and DMRs 
dependent on cell type purity (cell line > laser capture microdissected FFPE 
> FF). All DMRs associated with Cadherin genes had sample-permutation 
estimated P < 0.05. Profiles of these are displayed in Figure 3.18. In 
summary, 43 genes with promoter hypermethylation were found consistently 
across all datasets (permutation FDR 10%) including multiple Cadherin 
genes and other PRC2 targets. In addition, five genes were found (SNTB1, 
CYP7B1, MEI1, ICA1, and FAM163A) with hypomethylated promoter DMRs. 
 
 
Figure 3.18: Profiles of hypermethylated TSS200 promoter DMRs of Cadherin genes 
(across FFPE HNSCCs, FF HNSCCs and HNSCC cell lines), namely CDH8, PCDH10 and 
PCDH15. Feature annotation is as provided by BeadChip and methylation values are colour-
coded accordingly: TSS1500 = orange (1500 bp – 200 bp upstream of the transcription start 
site), TSS200 = red (200 bp upstream of the transcription start site), 5’UTR = yellow, gene 
body = blue, CpG islands = black, CpG shores = grey and CpG shelves = light grey.  
 
3.1.7 Integration with publicly available gene expression data 
 For additional functional evidence of the effect of DNA methylation 
changes on gene expression, the observed methylation differences between 
HPV+ and HPV- FFPE tumour samples were compared with publicly 
available gene expression data [20]. The top 500 MVPs mapping to CpG 
islands were compared with the differential expression t-statistics of their 
associated genes. A significant negative correlation was observed (Wilcox P 
= 2e-18; Figure 3.19A). A list of genes with consistent TSS200 DMRs across 
all datasets (FFPE HNSCCs, FF HNSCCs, HNSCC cell lines) and which also 
exhibited differential gene expression in the independent Pyeon gene 
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expression data set is shown in Figure 3.19B. Among these were 3 Cadherin 
genes (CDH8, PCDH10 and PCDHB11). These data are consistent with 
Cadherin genes being targets for HPV-mediated hypermethylation and 
transcriptional silencing in HNSCC.  
 
 
Figure 3.19: Integration of DNA methylation data with public gene expression data.  
A) DNA methylation correlates with decreased gene expression: scatterplot of t-statistics 
between HPV+ and HPV- FFPE cancer samples (top 500 differentially methylated MVPs 
restricted to CpG islands) shows significant anticorrelation between DNA methylation and 
gene expression. Gene expression data were from (Pyeon et al., 2007). 
B) List of top 10 anticorrelated targets: Differentially methylated genes in promoter region 
(TSS200) which also exhibit differential gene expression in the independent Pyeon gene 
expression data set. 3 Cadherin genes are found among the top10 hits (bold). 
 
3.2 Discussion of results obtained in chapter 3. 
  
My findings reported in this chapter represent the most comprehensive 
epigenetic study of a virus-induced cancer known to date and the first to 
validate the existence of an HPV-mediated DNA methylation signature in 
HPV+ HNSCC. Supported by extensive validation using independent 
samples and different methods, the signature showed a clear skew towards 
hypermethylation which was most prominent at promoter regions (defined by 
TSS200). However, there was also significant hypomethylation at gene 
bodies which, together with promoter hypermethylation, is a clear hallmark of 
gene silencing [160]. It is well documented for instance that hypermethylation 
of the promoter region of tumour suppressor genes plays an important role in 
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cellular transformation [161] and indeed consistent hypermethylation (defined 
by both hyper-MVPs and hyper-DMRs) was found in the promoter regions of 
such genes as well a candidate CIMP in the HPV+ samples. CIMPs have 
been observed in a number of cancers, including colon cancer [162], brain 
cancer [159] and breast cancer [158]. In all cases reported so far, CIMP has 
been associated with a favourable clinical outcome. HPV+ HNSCC patients 
are also associated with a more favourable outcome [15] but the candidate 
CIMP observed here was only present in a sub-group of four HPV+ patients 
who all had a shorter survival and recorded death. To my knowledge, this is 
the first time that a CIMP (albeit a candidate CIMP) is associated with 
potentially less favourable clinical outcome. Furthermore, I was able to show 
that my signature (defined by top 1000 MVPs) was independent of gender 
and predictive for smoking status and length of survival, confirming previous 
findings [8, 15, 163].  
 The inclusion of multiple sample types (FFPE, FF and cell lines) in the 
validation part revealed an important observation with direct implications for 
projects with an epigenetic biomarker component such as ICGC 
(http://www.icgc.org/), IHEC (http://www.ihec-epigenomes.org/), OncoTrack 
(http://www.oncotrack.eu/) and others. While FF samples have emerged as 
gold-standard for the genomic analysis of cancer, my data demonstrate that 
archival FFPE samples may be superior for certain epigenomic analyses, 
particularly when combined with laser-capture microdissection as illustrated 
in Figure 3.17. The largest differences in DNA methylation levels were 
consistently observed in cell lines, followed by laser microdissected FFPE, 
followed by FF. This general trend was expected because DNA methylation 
is known to be cell-type specific but the evident high level of confounding 
cellular heterogeneity (resulting in dilution of the respective MVP/DMR 
signals) in carefully biobanked FF samples is nevertheless noteworthy.  
 The most interesting finding arising from the GSE analysis is the 
enrichment of numerous members of the Cadherin superfamily which are 
targets of PRC2 and are implicated in many cancers and cancer-specific 
processes [164], including epithelial to mesenchymal transition (EMT), a 
process by which carcinomas become invasive and acquire the ability to 
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metastasize [165]. Notable examples include E-Cadherin (CDH1), T-
Cadherin (CDH13) and Proto-Cadherin 10 (PCDH10) which are recognized 
tumour suppressor genes and have been found hypermethylated in a number 
of human cancers [164]. Among the 49 PRC2 targets (defined by consistent 
hyper-MVPs) identified here were 10 genes of the Cadherin superfamily in 
HPV+ HNSCC, including CDH8 and CDH13 (both also hypermethylated in 
cervical cancer [166], CDH18, CDH19, CDH23, PCDH10, PCDH15, 
PCDHB1, PCDHB4 and PCDHB15. Moreover, the 11 MVPs in 6 Cadherin 
genes identified amongst the top 1000 MVPs by unsupervised clustering 
analysis of FFPE HNSCC samples, warrant further investigation as potential 
biomarkers as they clustered my HPV+ and HPV– samples according to HPV 
status with high accuracy.  
 Two lines of evidence were obtained with respect to functional support 
for the identified hypermethylation signature. First, I was able to partially 
phenocopy the signature by ectopic expression of the two HPV oncogenes 
E6 and E7 in a HPV- HNSCC cell line. Combinatorial analysis showed that 
E6 is one of the main viral effector genes. The underlying mechanism 
remains unknown and is subject to future work such as analysis of cross-talk 
between E6 and DNA methyltransferases (DNMTs), effect of E6 on TP53, 
number and distribution of viral integration sites into the host genome and the 
viral methylome itself. Second, integration of publicly available expression 
data with my DNA methylation data [20] was performed. Among the top 10 
anticorrelated (high promoter methylation and low expression) genes were 
three of the Cadherins, namely CDH8, PCDH10 and PCDHB11. The inverse 
scenario (low promoter methylation and high expression) was also observed 
and both are likely to contribute to the different clinical behaviour of HPV+ 
and HPV- HNSCC with regard to survival and response to therapy. Linking 
these two lines of evidence suggests a possible mechanism whereby HPV 
could drive tumour progression by promoting epithelial to mesenchymal 
transition (EMT) [165] through epigenetic silencing of Cadherins in addition to 
its established role in tumour initiation.  
 In conclusion, this work significantly advances the understanding of 
the epigenetic dynamics at genomic loci targeted by oncogenic viruses as 
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demonstrated here for loci associated with the infection of HPV in HNSCC. 
Based on the previously established finding (supported by the results of my 
survival analysis outlined in section 3.1.1) that HPV+ HNSCC patients have a 
better prognosis than HPV- patients, it is tempting to speculate that this 
advantage may be partly epigenetically mediated. My results certainly 
implicate DNA methylation in this process. If confirmed, targeted 
reprogramming of the identified HPV-mediated hypermethylation signature 
(or parts of it) in HPV- patients offers an immediate translational application 
for my finding. Although still at an early experimental stage, targeted 
reprogramming has recently been demonstrated, including in cancer cells 
[167, 168]. In the longer-term, these data will contribute to the identification of 
diagnostic and prognostic markers, as well as putative therapeutic targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Chapter 4: Analysis of the Viral 
Methylome in HPV-associated Head 
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and Neck Cancer and associated 
changes in viral gene expression 
 
Chapter 4 
  
Analysis of the Viral Methylome in  
HPV+ Head and Neck Cancer  
 
This chapter describes the methylation analysis of the HPV genome in my 
set of HNSCC samples and the validation of the obtained results in these 
HNSCC samples, in HNSCC cell lines and in an independent sample set of a 
different type of HPV-induced cancer. It also describes differences in L1 and 
L2 expression, associated with the methylation status of the identified 
methylated CpG sites. 
 
4.1 Results. 
 
4.1.1 HPV type 16 was confirmed in all HPV+ samples and 
methylation within the viral genome was demonstrated: 
 
All FF HPV+ HNSCC were found to contain copies of HPV type 16, as tested 
by MeDIP-Seq. In brief, the obtained normalized reads of the 3 HPV+ 
HNSCC samples were successfully aligned against the HPV type 16 genome 
(NC_001526). The sequenced reads from HPV- HNSCC samples (tested by 
E6 qPCR initially) that did not align to the HPV type 16 genome (NC_001526) 
were further aligned to 1776 available viral genomes. None of these reads 
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aligned to any of the 29 available human papilloma viruses (Table 2.13), 
obtained from NCBI Genomes (http://www.ncbi.nlm.nih.gov/genomes/ 
GenomesHome.cgi?taxid=10239), such as HPV type 18 (NC_001357) and 
others. 
By applying the MeDIP-Seq technology methylation changes within the HPV 
type 16 genome in HNSCC were demonstrated. After normalization of reads 
from these 3 HPV+ FF HNSCC samples according to average HPV copy 
number per cell for all three samples (Sample #39: 96,94 copies per cell; 
#105: 110.44 copies per cell; #125: 0.66 copies per cell) in reads per million, 
RPM, the relative methylation levels were calculated within the viral genome 
(Figure 4.1). 
 
Figure 4.1: HPV type 16 methylome in HNSCC. Sites of methylation within the viral genome 
were mainly detected at the boundary of the L1/L2 ORF and within the E1 ORF (created in 
Circos [169]).  
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These methylation changes were particularly observed at the boundary of the 
L1 and the L2 gene and within the E1 gene (Figure 4.1). Methylation in the 
boundary region was detected in all samples investigated. The sequence of 
this part of the viral genome harbours 6 CpG sites at genomic position 5600, 
5606, 5609, 5615, 5707, and 5724. The first 4 CpG sites are located within a 
sequence of only 16 bp and the remaining 2 follow 92 bp and 109 bp 
downstream, respectively (Figure 2.7). 
 
4.1.2 Validation of methylation at the boundary of the L1/L2 ORF of 
the viral genome in FF HNSCC samples and in an independent set of 
HPV+ HNSCC cell lines by BS-Seq: 
The results obtained by MeDIP-Seq were validated by applying the BS-Seq 
technique on a 421 bp PCR product of the viral genome, covering the 6 CpG 
sites of interest and two additional CpG sites in genomic positions 5925 and 
5961, in the 3 FF HPV+ HNSCC samples (Figure 4.2). BS-Seq was also 
used to test the methylation status of this region in 3 HPV+ HNSCC cell lines 
(UPCI:SCC90, UM:SCC47, 93VU-147T) and methylation at all 6 CpG sites at 
genomic positions 5600, 5606, 5609, 5615, 5707, and 5724 was observed 
(Figure 4.2). 
4.1.3 5-AZA treatment of HPV+ HNSCC cell lines and its effect on L1 
and L2 expression: 
Three HPV+ HNSCC cell lines (UPCI:SCC90, 93VU-147T, UM:SCC47) were 
incubated with increasing amounts of 5-AZA (1 µM, 2 µM, 5 µM, 10 µM) for 
72 hours. 
Employing L1 RT qPCR and L2 RT qPCR, L1 and L2 viral gene expression 
levels were measured. No significant increase in L1 expression was 
observed in any cell line upon treatment with 5-AZA (Figure 4.3).  
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Figure 4.2: Methylation of the L1/2 boundary region is observed in all tested FF HPV type 
16+ HNSCC tissue samples and 3 HPV type 16+ HNSCC cell lines (UPCI:SCC90, 
UM:SCC47, 93VU-147T). Selected BS-Seq traces, covering the 6 CpG sites of interest, are 
illustrated along with the positive (in vitro methylated DNA from UPCI:SCC90) and negative 
(whole-genome amplified DNA from UPCI:SCC90) control at six CpG sites at genomic 
position 5600, 5606, 5609, 5615, 5707, and 5724 of the HPV type 16 genome. 
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Figure 4.3: Log-fold change of L1 gene expression in UPCI:SCC90, 93VU-147T and 
UM:SCC47 upon treatment with increasing amounts of 5-AZA (1 µM, 2 µM, 5 µM, 10 µM) for 
72 hours. 
A significant increase in L2 expression was observed in 93VU-147T upon 
treatment with 5-AZA at concentrations of 2 µM, 5 µM, and 10 µM for 72 
hours. No significant increase of L2 gene expression was observed in 
UPCI:SCC90 and UM:SCC47 under the same conditions (Figure 4.4).  
 
Figure 4.4: Log-fold change of L2 gene expression in UPCI:SCC90, 93VU-147T and 
UM:SCC47 upon treatment with increasing amounts of 5-AZA (1 µM, 2 µM, 5 µM, 10 µM) for 
72 hours. A significant increase in L2 expression was observed in 93VU-147T after 
incubation with 5-AZA at concentrations of 2 µM (P < 0.01; unpaired T-test), 5 µM (P < 0.05; 
unpaired T-test), and 10 µM (P < 0.01; unpaired T-test) for 72 hours. 
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The methylation status of the L1/L2 boundary region upon treatment with 1 
µM, 2 µM, 5 µM, and 10 µM of 5-AZA was tested using the BS-Seq 
technique, as described in method section 2.4.2. No demethylation of this 
locus was observed in any cell line after incubation of cell lines with the 
tested concentrations of 5-AZA. 
In summary, this preliminary experiment of head and neck cancer cell lines, 
shows a significant increase in L2 gene expression in a single cell line 
(93VU-147T) upon treatment with 5-AZA only. No significant gene expression 
change was found in any other tested cell line. No change of the methylation 
status at this locus (tested by BS-Seq) was observed upon treatment with 5-
AZA.  
4.1.4 Integration sites identified within the host genome: 
By selecting for paired-end reads of which one aligned with high confidence 
to HPV type 16 and the other to human DNA, enrichment of these reads 
(‘integration site’ reads) within genomic locations was calculated. The 
probability of an ‘integration site’ read aligning to a specific genomic region 
was weighted according to the total number of reads aligning in the chosen 
window. The resulting empirical P-values were log transformed (-log10) and 
plotted along the HPV type 16 genome. Thereby, viral integration sites within 
the host genome were identified. 
The integration sites across the human genome appear to be random, 
whereas there is a significant enrichment of potential integration sites within 
the viral E2 (E4 and E5) region, as illustrated in Figure 4.5 and Figure 4.6. A 
possible explanation for this is discussed in section 4.2. 
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Figure 4.5: Potential integration sites of HPV type 16 in the human genome and illustration 
of location of ‘integration site reads’ in the HPV genome, representing the genomic region of 
the virus disrupted during the integration process. Links coloured dark blue indicate those 
located in the HPV region most significantly enriched for integration sites. HPV and human 
genome drawn at different scale (created in Circos [169]). 
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Figure 4.6: Enrichment of potential integration sites in the HPV genome as measured by –
log transformed empirical P-value. Region containing the E2, E4 and E5 genes display the 
most significant degree of enrichment. 
 
4.2 Discussion of results obtained in chapter 4. 
 
In line with previous reports, showing that HPV type 16 is found in almost all 
cases of HPV+ HNSCC [28], all FF HPV+ HNSCC samples tested in this 
thesis had integrated copies of HPV type 16 only. 
By employing the MeDIP-Seq technology on HNSCC samples, allowing the 
interrogation of 100% of the HPV methylome, methylation within one region 
of the HPV type 16 genome was detected consistently across all samples. 
This 124 bp region lies at the boundary of the L1 and the L2 gene and 
harbours a total of 6 CpG sites. 
Methylation in this specific location has previously been shown in cervical 
cancer [103, 114]. Fernandez et al. showed that methylated CpG sites within 
this region of both the HPV type 16 and HPV type 18 genome is present in 
the majority of cervical cancer samples tested, rather than in premalignant 
cervical lesions and in carriers [103]. As part of their comprehensive HPV 
type 16 methylome analysis Park et al. assessed the methylation status of 
this region in advanced stage III/IV HNSCC patients [119]. Although, not 
specifically mentioned by the authors, they found consistent methylation of 
CpGs within this region across every sample tested. The main result 
presented by Park et al. was that large parts of the HPV type 16 genome, in 
particular the long-control region (LCR), which controls transcription of the E6 
LCR 
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and E7 oncogenes [25], was found to be unmethylated in the majority of 
examined cases. In line with the findings by Park et al. the LCR region is 
found unmethylated in all FF HPV+ HNSCC samples tested in this thesis, 
suggesting that methylation in this genomic location may be a rare event in 
HNSCC. The LCR region harbours multiple binding sites for E2. Methylation 
within the LCR is known to prevent the binding of E2, thereby increasing the 
expression of E6 and E7, the two key oncogenes [104]. Thus, one would 
expect to find methylated CpG sites within this region. One explanation may 
be that, as the E2 gene is often disrupted or lost upon viral integration, the 
selective pressure to methylate this genomic segment is lost in the absence 
of the transcriptional repressor E2 [119]. 
Based on the findings by Fernandez et al., it is conceivable that methylation 
of the viral genome plays an important role in HPV-induced carcinogenesis, 
rather than a bystander role only. Moreover, the boundary of the L1 and L2 
gene is reported more frequently methylated in cervical cancer samples than 
in premalignant and normal tissue [114]. Hence, the question arises whether 
methylation of this site is directed by the virus or rendered by a potential host 
defence mechanism. The HPV genome does not encode for any DNA 
methyltransferase (DNMT) and thus it is believed that the viral genome is 
methylated by the human host cell DNMTs [104]. This may either be directed 
by the virus through cross-talk between viral proteins and DNMTs (in order to 
regulate intrinsic cell-differentiation dependent [113] and temporal viral gene 
expression) or it may represent a potential host defence mechanism, with the 
host aiming to alter viral gene expression to avoid viral proteins disrupting 
normal cellular function. Assuming a cybernetic model of carcinogenesis, it is 
likely that both processes take place at the same time with abundant paths of 
interaction. 
Having confirmed the absence of methylation within the late gene promoter 
P670 (within the E7 viral gene region) by MeDIP-Seq, it was tempting to test 
whether methylation at the L1/L2 boundary region may have some influence 
on the expression of late genes. Preliminary L1 and L2 gene expression data 
after 5-AZA treatment in HPV+ HNSCC cell lines showed no significant 
change of expression in tested cell lines apart from a significant change in L2 
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expression in 93VU-147T. No change of methylation of the L1/2 boundary 
region was observed upon treatment with 5-AZA. This region of interest 
remains fully methylated at all concentrations of 5-AZA used and suggests 
that this locus may be resistant to the effect of 5-AZA. This of course raises 
the question why a change in L2 expression was observed in 93VU-147T, 
although the methylation status of the tested CpG sites remained unchanged. 
This may point towards an epigenetic mechanism of L2 regulation which is 
unrelated to changes in the examined region. However, it has to be 
acknowledged that these expression data are very preliminary and potential 
explanations provided are only speculative. Further experiments need to be 
carefully planned and are subject to future work.  
Irrespective of the potential effects of methylation in this specific location, it 
may serve as a diagnostic biomarker for HPV+ HNSCC. Park et al. employed 
MSP to test for LCR methylation status in serum and saliva samples of HPV+ 
HNSCC patients. As no control group was included in that study, it can be 
regarded as a successful feasibility trial [119]. However, based on the 
findings discussed in this section and the results by Brandsma et al. [114] 
and Fernandez et al. [103], testing the methylation status of this region at the 
boundary of L1/L2 in serum and saliva samples may represent a far more 
powerful diagnostic biomarker. 
 
Apart from methylation at the L1/2 boundary region of the viral genome, 
methylation within the E1 gene was detected to varying degrees in the FF 
HPV+ HNSCC tissue dataset. The significance of these findings remains to 
be investigated. 
One of the main advantages of having employed MeDIP-Seq is that potential 
integration sites can be detected by selecting for paired-end reads that align 
both to the viral and host genome (‘integration site reads’). This is a far more 
reliable method than calculating the ratio of E2 and E6 viral gene expression 
as a measure of integrated vs. episomal HPV type 16 [119], owing to the fact 
that E2 is frequently disrupted during the integration of the viral genome into 
the host genome [42]. My data show that integration sites across the human 
genome appear to be random. However, there was a significant enrichment 
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of potential ‘integration site reads’ within the viral E2 (E4 and E5) region, 
suggesting that this is a common location of disruption of the viral sequence 
upon integration into the host genome in HNSCC. This is in line with 
evidence, showing that disruption of the HPV genome at this location upon 
integration is a common and early event in the history of cervical HPV 
infection [42]. Limitations to the current findings are that only a small set of 
samples were used for analysis and that relatively few ‘integration site reads’ 
were detected Thus, the described integration sites within the host genome 
will have to be evaluated further in a larger set of samples.  
 
In conclusion, the obtained methylation data, having mapped the entire HPV 
type 16 methylome in HNSCC and having detected methylation at CpG sites 
within a region at the boundary of the L1 and L2 gene, along with findings 
reported in cervical cancer, suggest that this may not only represent a 
significant event in HPV-induced carcinogenesis, but may also lead the way 
to the identification of novel diagnostic markers for HPV+ HNSCC. 
 
  
 
 
 
 
 
 
5. Chapter 5: Genomic Analysis of HPV+ and HPV- 
HNSCC 
 
 
110 
 
 
 
 
 
Chapter 5 
 
Genomic Analysis of HPV+ and HPV- HNSCC 
 
This chapter describes the results of the genomic analysis of HPV+, 
compared with HPV- HNSCC, and discusses the findings. 
 
5.1 Results. 
5.1.1 Patient demographic data: 
The median age was slightly higher in the HPV- group (58 vs. 56.5 years) 
(Table 2.4). The male to female ratio was similar between the groups, and 
the majority of cases showed moderately or poorly differentiated histology 
with evidence of lymph nodal involvement at presentation. In my cohort, as 
predicted, the vast majority of HPV- cases were active smokers and/or heavy 
alcohol users (Figure 5.1). 
5.1.2 Exon-sequencing:  
Paired-end sequencing of hybrid-captured DNA, targeting 3,230 exons in 182 
genes often mutated in cancer was employed. The sequence analysis 
revealed that HPV+ and HPV- oropharyngeal carcinomas cluster into two 
distinct subgroups, with few overlapping genetic alterations (Figure 5.1 and 
Figure 5.2A). TP53, PIK3CA, CCND1, CDKN2A together with CDKN2B, 
PTEN, FBXW7, and SOX2 were among the most frequently genetically 
altered genes (>10% of HNSCC cases).  
TP53 mutations are detected in 100% of HPV- samples (Figure 5.1) and the 
list of observed TP53 mutations is illustrated in Table 5.1. HPV+ and HPV- 
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HNSCC samples clustered, but not into two distinct subgroups after 
exclusion of the TP53 mutation data (Figure 5.2B).  
 
 
Figure 5.1: Illustration of somatic events in HPV+ and HPV- HNSCC revealed by deep 
sequencing. Relevant demographic and histological data are described above the heatmap 
of genomic changes. The colour coding of the observed changes and patient characteristics 
are explained in the key on the right. 
 
Copy number alterations in CCND1 amplification and CDKN2A/B deletions 
were exclusively detected in HPV- cases (in around 55% and 40% of cases 
respectively). Comparing the overall survival of patients with a CCND1 
amplification (n=9), with the ones without a copy number alteration in this 
genomic location (n=25), a trend towards a worse outcome for patients 
harbouring the amplification is observed (Figure 5.3; P = 0.0855; Log Rank 
test). The Cox regression model (proportional hazard model) which was fitted 
showed a weak trend towards CCND1 amplification in HNSCC (P ~ 0.0945 
with a hazard ratio of ~2.3, corresponding to a 130% increase in the risk of 
dying at any moment).  
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Table 5.1: List of TP53 mutations revealed by deep sequencing in HPV+ and HPV- HNSCC 
samples.  
Sample names TP53 mutations
P6_pos R290C
P8_pos
P13_pos
P19_pos
P26_pos
P28_pos
P35_pos
P38_pos
P43_pos
P50_pos
P60_pos
P67_pos
P72_pos
P74_pos
P79_pos
P82_pos
P83_pos
P105_pos
P7_neg R175H
P10_neg Y234H
P12_neg Y220S
P14_neg R273L
P17_neg G154fs
P24_neg L130fs
P25_neg Q165
P29_neg Y236
P40_neg R306
P62_neg Y220C
P70_neg Q104
P90_neg L114fs, L330fs
P91_neg R337L
P92_neg R335L, G334V
P94_neg T155P
P95_neg 920-1C>T splice
113 
 
PIK3CA mutation or amplification, and PTEN inactivation by gene copy loss 
or mutation were seen in over 60% of HPV+ tumours, and in 31% HPV- 
tumours. FBXW7 alterations were present in over 15% of all samples and 
SOX2 amplification in 12% of cases (Figure 5.1).   
 
 
 
 
Figure 5.2: (A) Hierarchical clustering of HPV+ and HPV- HNSCC samples using all 
detected genetic changes. One HPV+ sample (P83_pos; heavy smoker) has an RB1 
mutation and clusters with the HPV- group.  
(B) Hierarchical clustering excluding mutations within TP53 reveals that HPV+ and HPV- 
tumours do not cluster into two distinct subgroups.  
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Figure 5.3: Kaplan Meier Plot. Survival analysis, comparing the overall survival of 9 HNSCC 
patients with a CCND1 amplification in their tumour tissue with the 25 patients without. A 
trend was observed for overall survival (log rank test; P = 0.0855)  
  
5.1.3 Validation of obtained results: 
To validate the results, Infinium CNV profiling, Sequenom OncoCarta panels 
v1.0 and v3.0 and immunohistochemistry was applied. Copy number gains 
and losses detected by next-generation sequencing (NGS) were interrogated 
by Infinium CNV profiling.  42 of 44 (95%) copy number alterations detected 
by sequencing were confirmed (Figure 5.4).  
 
In order to obtain a global picture, I mapped all copy number alterations 
detected by Infinium CNV profiling. Comparing the obtained genome-wide 
copy number alteration profiles between HPV+ and HPV- HNSCCs revealed 
that overall, similar genomic regions harbour concordant copy number 
changes in both groups (in particular in chromosomes 3, 7 and 14). 
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Amplification of 3q seems to be a particular target in both HPV+ and HPV- 
HNSCC lesions (Figure 5.5). 
 
A  
 
 
Figure 5.4: Validation of copy number changes by Infinium CNV profiling across all samples.  
A) 42 of 44 (95%) copy number alterations detected by sequencing were confirmed (green: 
confirmed, pink: not confirmed, grey: no data); 
B) Genetic changes in ‘P17_neg’ detected by NGS (extracted from Figure 1); C) Illustration 
of copy number changes (obtained from Infinium CNV profiling) in ‘P17_neg’. Both the loss 
of the CDKN2A and CDKN2B genes (in a region of loss within chromosome 9) and the gain 
of the CCND1 gene (in an amplified region of chromosome 11) are shown. Y-axis: log fold 
change of copy number, X-axis: copy number changes across all chromosomes. 
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Figure 5.5: Infinium CNV profiling of HPV+ and HPV- HNSCC samples.  
Comparing the obtained genome-wide copy number alteration profiles between the two 
groups, it is evident that the same regions are found to harbour concordant copy number 
changes in both HPV+ and HPV- HNSCC samples (in particular in chromosomes 3, 7 and 
14). This may point towards common molecular pathways in the pathogenesis of both HPV+ 
and HPV- cancers. Chromosome 6 (MHC regions) and Y chromosome are not shown. 
 
Furthermore, the detected mutations by NGS were validated by Sequenom 
OncoCarta panels v1.0 and v3.0 (Figure 5.6). Since the applied NGS targets 
all exons of all genes tested, whilst Sequenom OncoCarta panels target only 
specific mutational hotspots of certain genes, it follows that the majority of 
NGS detected mutations were not included in the Sequenom analysis.  Eight 
out of 9 mutations that were detected by NGS were also confirmed by 
Sequenom. One PIK3CA mutation in sample P72_pos was called at 1% 
allele frequency by NGS, and this mutation was therefore unlikely to be 
detected by Sequenom analysis.  
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Figure 5.6: Validation of detected mutations by Sequenom OncoCarta panels v1.0 and v3.0.  
Mutations in HNSCC samples detected by deep sequencing were validated using the 
OncoCarta panels v1.0 and v3.0. 8 out of 9 mutations that were successfully tested on the 
Oncocarta panel were confirmed (green: confirmed, pink: not confirmed, grey: n/a). *The 
PIK3CA_E545K mutation in sample P72_pos was called at 1% allele frequency by NGS, and 
this mutation was therefore unlikely to be detected by Sequenom analysis.  
 
In order to obtain a further line of evidence, findings from the genomic 
analysis were validated by immunohistochemistry for two frequently 
genetically altered genes: CCND1 and PTEN. Genomic alterations in CCND1 
were confirmed by Cyclin D1 immunochemistry with strong expression of the 
Cyclin D1 protein in 8 of 9 CCND1 amplified cases (and intermediate 
expression in the remaining case). Representative samples are shown in 
Figure 5.7.  
* 
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Figure 5.7: Validation of detected copy number alterations of Cyclin D1 (CCND1) by 
immunohistochemistry.  
Staining of HNSCC samples for Cyclin D1 confirmed strong expression in 8 of 9 CCND1 
amplified cases (and intermediate expression in the remaining case) compared with samples 
harbouring no copy number alteration; Representative samples shown: Low levels of 
CCND1 expression in the tumour tissue of sample ‘P38_pos’ (A) and sample ‘P29_neg’ (B); 
Deep-sequencing: No CNA; High levels of Cyclin D1 expression in the tumour tissue of 
sample ‘P12_neg’ (C) and sample ‘P17_neg’ (D); Deep-sequencing: CCND1 copy number 
gain. 
 
PTEN loss and mutation was validated by immunohistochemistry (Figure 
5.8). PTEN staining was negative in all cases in which deep sequencing 
revealed a homozygous deletion or mutation. Four additional samples 
displayed low PTEN protein expression. In three of these cases a 
heterozygous deletion/single copy loss of PTEN was present, as detected by 
NGS. In the remaining sample other mechanisms may explain the loss of 
expression, such as an epigenetic alteration or changes in the 
posttranscriptional regulation of PTEN. 
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Figure 5.8: Validation of detected PTEN copy number loss by immunohistochemistry.  
Staining of HNSCC samples for PTEN was negative in all cases in which deep sequencing 
revealed a homozygous deletion or mutation.  
Representative samples shown: Abundant PTEN expression in the tumour tissue of sample 
‘P26_pos’ (A) and sample ‘P70_neg’ (B); Deep-sequencing: No CNA; Absence of PTEN 
protein in the tumour tissue of sample ‘P60_pos’ (C) and sample ‘P13_pos’ (D); Deep-
sequencing: PTEN copy number loss. 
 
5.2 Discussion of results obtained in chapter 5. 
 
Overall, sequence analysis revealed that HPV+ and HPV- oropharyngeal 
carcinomas cluster into two distinct subgroups, with few overlapping genetic 
alterations. These data concur with epidemiological and clinical data, 
indicating that HPV+ HNSCC is a distinct disease entity [8, 9]. 
The fact that targeted deep next-generation sequencing revealed that TP53 
is mutated in 100% of HPV- samples indicates that TP53 is likely to be a 
ubiquitous early event in the pathogenesis of oropharyngeal HNSCC. 
Previous studies suggested that 60-85% of HNSCC cases test positive for 
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TP53 mutations [51]. In HPV+ disease, E6 leads to TP53 functional 
inactivation. Consistent with this, only one TP53 mutation was identified in an 
HPV+ tumour. However, this mutation (R290C, Table 5.1) causes only a 40% 
decrease in TP53 function and has been detected in sarcomas harbouring 
MDM2 amplification [170, 171]. One caveat in my study is that all HPV- 
samples analysed were also p16 negative, thus it remains possible that in 
HPV- samples with elevated p16 expression (e.g. through RB1 mutation), the 
frequency of TP53 mutation is less than 100%.  
The obtained data for HPV- oropharyngeal cancer indicate that the frequency 
of CCND1 amplification (in around 55% of cases) and CDKN2A/B deletions 
(in around 40% of cases) are higher than previously reported [172]. CCND1 
amplification has also been described in 12% of non-small cell lung cancers 
[173] and in up to 41% oesophageal squamous cell carcinoma [174], 
suggesting that this could be one of the more common genetic alterations 
linked to smoking-induced epithelial malignancy. In HPV+ cancer, the 
oncoprotein E7 leads to cell cycle dysregulation by substituting for cyclin D 
gain-of-function and cyclin dependent kinase inhibitor loss-of-function 
activities. Overall, this indicates that direct dysregulation of the cell cycle is a 
key mechanism for oropharyngeal tumours to evolve. 
HPV+ HNSCC samples frequently harbour mutations or CNVs in genes 
implicated in activation of the PI3K/AKT/mTOR pathway. In particular, 
PIK3CA mutation and PTEN inactivation by gene copy loss or mutation were 
seen in over 60% of HPV+ tumours, and in 31% of HPV- tumours. These 
findings may help to explain the high frequency of PI3K pathway activation in 
HPV+ HNSCC samples and the efficacy of mTOR inhibitors in xenograft 
studies with HPV+ cell lines previously reported [175]. It will be important to 
audit both the sequence and copy number of the PIK3CA and PTEN genes if 
such agents are tested in clinical trials for HPV+ HNSCC. 
 
The obtained results suggest that mutations in FBXW7 may be enriched in 
HPV+ disease. FBXW7 is an E3 ubiquitin ligase that targets a number of 
growth-promoting proteins for proteasomal degradation, including Cyclin E, 
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MYC, NOTCH and mTOR [176, 177]. Loss of FBXW7 occurs in combination 
with NOTCH gain-of-function mutations in T-ALL [178], suggesting it may be 
an important target for FBXW7 ligase activity in these tumours. In contrast, 
HNSCC frequently display NOTCH loss-of-function-mutations [110, 179], 
thus in HNSCC, other substrates such as Cyclin E, MYC or mTOR may be 
the relevant targets for FBXW7.  
 
The SOX2 and PIK3CA genes both reside on the long arm of chromosome 3 
(3q26) and these genes were amplified in three HPV+ samples and one 
HPV- tumour. Amplification of 3q seems to be a particular target in both 
HPV+ and HPV- HNSCC lesions (Figure 5.5). While PIK3CA amplifications 
have previously been reported in HPV+ HNSCC [180, 181], SOX2 has 
recently been proposed as the critical target of 3q gains observed at a high 
frequency in squamous lung cancer [182] and in oesophageal squamous cell 
carcinoma [183]. SOX2 is also frequently amplified and overexpressed in oral 
squamous cell carcinoma [184]. Furthermore, SOX2 expression is 
upregulated in a subpopulation of putative HNSCC stem cells that displays 
characteristics of epithelial to mesenchymal transition (EMT), associated with 
increased propensity for metastasis [185].  
I also demonstrate inactivating mutations in NF1 and STK11 in HPV+ 
HNSCC for the first time. Loss of STK11 is associated with metastasis in 
head and neck cancer [186].  
Beyond the genes directly involved in signalling and cell cycle, I found 
amplifications in genes implicated in preventing apoptosis: BCL2L1 (6% 
amplification) and MCL1 (3% amplification), suggesting that suppression of 
apoptosis may also contribute to HNSCC pathogenesis.   
Receptor tyrosine kinase mutations, FGFR1, FGFR3 and EGFR, were only 
observed in HPV- tumours at low frequency.  
Overall, my data strongly support a causal role for HPV in oropharyngeal 
carcinogenesis by overcoming the requirement for genetic lesions in the 
TP53 and RB1 tumour suppressor pathways evident in the HPV- tumours. 
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The detection of frequent PI3K/AKT/mTOR pathway alterations in HPV+ 
tumours is consistent with a recent report demonstrating PI3K pathway 
activation and sensitivity to mTOR inhibition in both cervical carcinoma and 
HPV+ HNSCC [175]. Together, these studies provide a rationale for the 
testing of PI3K pathway inhibitors in HPV+ HNSCC. In HPV- tumours, the 
frequent alteration of CDKN2A/B and/or CCND1 suggests that, if supported 
by functional data, trials with CDK inhibitors may be indicated.  My data 
support the observations by gene expression microarrays and by genome-
wide methylation studies that HPV+ HNSCC is a distinct entity, with a distinct 
set of somatic alterations. However, it would appear that a core set of 
pathways (TP53, RB1/cell cycle and PI3K/AKT/mTOR) is compromised in 
both HPV+ and HPV- oropharyngeal tumours, thus targeted therapies 
directed against one or more of these pathways could be efficacious in both 
contexts.  
 
 
 
 
 
 
6. Chapter 6: Integration of obtained data - 
Updating the current model of HNSCC 
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Chapter 6 
 
Integration of obtained data – 
 Updating the current model of HNSCC 
 
Having discussed the individual results in chapters 3, 4, and 5, this 
chapter will endeavour to collate the various results in order to integrate them 
and to present an updated model of head and neck cancer. 
 
6.1. Results 
 
6.1.1 Integration of obtained methylation data from HPV+ and HPV- 
HNSCC with publicly available methylation data on HPV-driven 
cancer (cervical cancer) and smoking-induced cancer (lung 
cancer): 
In order to test the effect of HPV on DNA methylation further, methylation 
data obtained from the 18 HPV+ and 14 HPV- HNSCC samples were 
integrated with publicly available methylation data on HPV-induced vs. 
smoking-induced cancer, 48 cervical cancer samples [154] and 59 lung 
cancer samples [153], respectively. Using a selection of HPV-associated vs. 
smoking-associated features (see method section), identified by comparing 
HPV+ with HPV- HNSCC, multidimensional scaling of the datasets using a 
simple Euclidean distance measure was applied and distances were plotted. 
An overlap of cervical cancer samples and HPV+ HNSCC samples was 
observed (Figure 6.1). Significance of this observation was further tested 
using a Wilcoxon rank sum test on intersample distances. When focusing 
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upon HPV+/HPV- methylation signatures the methylation pattern of cervical 
cancer samples was more closely related to the HPV+ signature observed in 
HNSCC (P < 2.2e-16). This suggests that HPV induces a distinct methylation 
signature that is independent of tissue-specific DNA methylation.  
 
Figure 6.1: Multidimensional scaling using the 4 datasets, comprising of 48 cervical cancer 
samples (CERV; pink), 59 lung cancer samples (LUNG; purple), 18 HPV+ HNSCC samples 
(HPV1; light-blue) and 14 HPV- HNSCC samples (HPV0; green), using a selection of HPV-
associated vs. smoking associated features identified by comparing HPV+ vs. HPV- 
HNSCC. 
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6.1.2 Integration of obtained genomic data from HPV+ and HPV- 
HNSCC with mutation data from HPV-driven cancer (cervical 
cancer) and smoking-induced cancer (lung cancer): 
The genomic data obtained from 18 HPV+ and 16 HPV- HNSCC tissue 
samples (chapter 5) were integrated with publicly available mutation data on 
HPV-induced vs. smoking-induced cancer. Mutation data for cervical cancer 
and lung cancer samples were obtained from the COSMIC database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic) with one report cited from 
the literature [187]. The most common mutations in these cancers are 
summarized in Table 6.1. 
 
 HPV+ HNSCC HPV- HNSCC 
Cervical 
Cancer 
Lung Cancer 
TP53 6% 100% 6% 36%; >90%* 
PIK3CA 33% 19% 11% 3% 
KRAS 11% 0% 9% 16% 
EGFR 0% 13% 0% 27% 
PTEN 22% 6% 5% 3% 
CDKN2A 0% 44% 9% 13% 
STK11 6% 0% 16% 9% 
* 36% of cases reported to be mutated in lung adenocarcinoma (COSMIC); >90% of cases 
reported to be mutated in SCLC [187]. 
 
Table 6.1: Percentage of somatic mutations (and genomic alterations in the cases of 
HNSCC) found within the listed genes, comparing the obtained NGS data on HPV+ HNSCC 
and HPV- HNSCC with publicly available mutation data on cervical cancer and lung cancer 
(Data obtained from the COSMIC database; http://www.sanger.ac.uk/genetics/CGP/cosmic). 
 
TP53 mutations are rarely found in the two investigated HPV-induced 
cancers (outlined in Table 6.1) in which viral protein E6 causes the 
degradation of TP53. PIK3CA amplifications and mutations are found in both 
HPV-induced cancer and cancers caused by other carcinogens, although the 
mutation rates for this gene appear to be higher in HPV-induced cancers.  
KRAS mutations (commonly found in tumours of patients with a history of 
smoking [188] are reported to be present in 16% of lung cancers. KRAS 
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mutations were detected in my set of HPV+ HNSCCs in 2 cases, one patient 
is a heavy smoker and in the other patient the smoking status is unknown, 
suggesting that this may be a smoking-induced mutation. EGFR mutations 
seem to be an exclusive feature of smoking-induced cancer (13% and 27% in 
HPV- HNSCC and lung cancer, respectively, compared with 0% in HPV-
associated cancers). Moreover, PTEN mutations are present in all types of 
evaluated sample sets of cancer. In line with previous results, showing that 
CDKN2A loss is a common feature of HPV- HNSCC, CDKN2A loss is 
observed in nearly half of all cases of HPV- HNSCC. STK11, which was 
reported to be a highly significantly mutated gene in lung cancer, is also 
found mutated in HPV+ HNSCC and cervical cancer. 
Moreover, pathways affected and genetic changes observed in lung 
adenocarcinoma in a previous study [189] were integrated with the obtained 
genomic data on HPV+ and HPV- HNSCC. A remarkable overlap of genetic 
alterations between these different cancers is observed (Figure 6.2). 
 
 
 
Figure 6.2: Mutated pathways in HNSCC (according to mutations detected by NGS of 
selected genes as described) and integration of these data with mutation data from lung 
adenocarcinoma (*=significantly mutated in lung adenocarcinoma cases).  
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6.1.3 Integration of the obtained epigenetic and genetic changes in 
head and neck cancer models into the Hanahan and Weinberg 
model: 
As outlined in chapter 1, cancer is caused largely by the acquisition of 
biological capabilities, rendered by changes in the genome and the 
epigenome in a partly stochastic and partly directed multi-step process, with 
underlying genomic instability. Using the obtained data from HPV+ and HPV- 
HNSCC, observed genomic and epigenomic alterations were linked to 
hallmark capabilities (Figure 6.3), as defined by Hanahan and Weinberg [54].  
Figure 6.3: Link of the genomic and epigenomic changes found in HNSCC to the 10 
hallmark capabilities of cancer (adapted from [54]). 
Genomic and epigenomic alterations underlie the observed phenotypic 
abnormalities and, apart from infection with a high-risk strain of HPV in HPV+ 
cancers, are mediated by exposure to environmental or life-style factors in 
addition to genetic factors.  
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6.1.4 An updated model of HPV-driven and HPV independent head 
and neck carcinogenesis: 
In the following section, an updated model of HPV-driven and HPV 
independent carcinogenesis is presented which incorporates findings from 
my thesis which can be summarized as the UCL/UCLH Head and Neck 
Cancer Genome and Epigenome Project.  
 
 
Figure 6.4: Updated model of HPV-driven and HPV independent carcinogenesis with a 
focus on head and neck cancer. It reveals partially distinct and partially overlapping 
pathways of carcinogenesis in these two distinct subtypes. 
 
It reveals partially distinct and partially overlapping pathways of 
carcinogenesis in these two distinct subtypes with regard to clinical behaviour 
and epidemiological associations. Loss of TP53 function is central in 
malignant transformation in both cancers (present in 100% of cases in my set 
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of HNSCC). The resulting genomic instability renders the acquisition of 
common genomic alterations (such as gains and losses of entire 
chromosomal regions; see chapter 5). Alterations of the host methylome and 
the viral methylome, outlined in Figure 6.4, may be equally important and are 
discussed in chapters 3, 4, and 7. 
 
6.1.5 Utilizing the obtained data – on the way to a diagnostic 
biomarker: 
This section aims to test the suitability of the described genetic and 
epigenetic changes in HPV+ HNSCC, compared with HPV- HNSCC, for the 
development of biomarkers. 
In chapter 5 the obtained mutational profiles of HPV+ HNSCC and HPV- 
HNSCC (targeted NGS data) were used to cluster samples into groups. In 
the case when TP53 was part of the panel of candidate markers used, 
samples clustered into HPV+ and HPV- subgroups (apart from one sample). 
In the case when TP53 was excluded from the analysis, samples did not 
cluster into two groups according to HPV status. 
In order to increase the discriminatory power of the performed test, a panel of 
candidate epigenetic markers was included in the hierarchical clustering 
analysis. 11 MVPs annotated to Cadherin genes (and shown to be a strong 
classifier of HPV status in my set of HNSCC, as described in chapter 3) were 
added to the panel of candidate genetic markers. Hierarchical clustering 
analysis on HPV+ and HPV- HNSCC samples was then repeated, employing 
this combinatorial panel of genetic and epigenetic candidate markers.  
Using this combinatorial panel, HPV+ and HPV- HNSCC samples cluster into 
two distinct subgroups (100% of cases; Figure 6.5 A). Even when excluding 
the mutation status of TP53 in samples from the analysis, HPV+ and HPV- 
tumours still clustered into two distinct subgroups with one outlier (Figure 6.5 
B), using the same panel and clustering method. 
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Figure 6.5: Hierarchical Clustering (Euclidean distance measure) of HPV+ and HPV- 
HNSCC samples according to a panel of genetic (NGS data; chapter 5) and a panel of 
epigenetic markers (11 Cadherin-annotated probes; chapter 3).  
A) Hierarchical clustering reveals that HPV+ and HPV- tumours cluster into two distinct 
subgroups using the combinatorial panel of markers. 
B) After having excluded mutations within TP53 and using the same clustering method, 
HPV+ and HPV- tumours still cluster into two distinct subgroups with the exception of one 
outlier.  
 
In summary, this combinatorial panel of genetic and epigenetic candidate 
markers is likely to identify HPV+ and HPV- patients irrespective of TP53 
status. TP53 mutational status has not been examined in cases of mixed p16 
staining or in cases, showing a positive p16 and negative E6 qPCR result 
and vice versa (excluded from analysis). 
 
6.2 Discussion of results obtained in chapter 6: 
 
 
The results obtained in this chapter clearly show that factors contributing to 
HPV-induced head and neck carcinogenesis are distinct from HPV- HNSCC, 
but that common pathways are affected, with a cell gaining the spectrum of 
hallmark capabilities, as outlined by Hanahan and Weinberg [54], during 
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malignant transformation. The potential of the detected genetic and 
epigenetic changes to serve as a diagnostic biomarker is evaluated, but more 
work is needed to test the specificity and sensitivity of this panel of candidate 
markers in the clinical setting. Lastly, the obtained data were integrated into 
an updated model of head and neck carcinogenesis and shall be discussed 
in more detail in chapter 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Chapter 7: General Discussion and Future 
Directions 
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Chapter 7 
 
General Discussion and Future Directions 
 
Having discussed results in chapters 3, 4, 5 and 6 individually, this 
chapter summarizes the key findings of my work and evaluates these in the 
context of other HPV-induced and smoking-induced cancers. Furthermore, 
an updated model of head and neck carcinogenesis (defined in chapter 6), 
the value of observed genetic and epigenetic changes for the establishment 
of novel biomarkers and future directions will be discussed. 
In chapter 3, I tested the possible involvement of epigenetic modulation by 
HPV in HNSCC by conducting a genome-wide DNA methylation analysis. 
Using laser-capture microdissection of 42 FFPE HNSCCs, DNA methylation 
profiles of 18 HPV+ and 14 HPV- samples were generated. Unsupervised 
clustering over the most methylation variable positions (MVPs) showed that 
samples segregated according to HPV status, but also that HPV+ tumours 
are heterogeneous. Amongst the MVPs there was significant enrichment of 
those mapping to transcriptional start sites, leading to the identification of a 
CIMP in a sub-group of the HPV+ tumours. Supervised analysis revealed a 
strong preponderance (87%) of the MVPs towards hypermethylation in HPV+ 
HNSCC. This signature was validated in two sets of independent HPV+/HPV- 
HNSCC samples (FF and cell lines) using two independent methods 
(Infinium 450k and MeDIP-seq). Grouping of MVPs into functionally more 
significant DMRs and assigning them to genes for gene set enrichment 
analysis identified 43 hypermethylated promoter DMRs, including three 
Cadherins of the Polycomb group target genes. Integration with independent 
expression data showed a strong negative correlation, especially for the 
Cadherin gene family members. Combinatorial ectopic expression of the two 
HPV oncogenes (E6 and E7) in an HPV- HNSCC cell line partially 
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phenocopied the hypermethylation signature observed in HPV+ HNSCC 
tumours and established E6 as the main viral effector gene. My data 
establish archival FFPE tissue to be highly suitable for this type of methylome 
analysis and suggest that HPV modulates the HNSCC epigenome through 
hypermethylation of Polycomb repressive complex 2 target genes such as 
Cadherins which are implicated in tumour progression and metastasis. 
In addition to the evaluation of methylation changes in the host methylome, 
the methylation status of the HPV genome in HNSCC was determined. HPV 
type 16 was confirmed in all HPV+ samples tested and methylation within the 
viral genome was demonstrated. Methylation which was detected at the 
boundary of the L1/L2 gene of the viral genome was validated in FF HNSCC 
samples and in an independent set of HPV+ HNSCC cell lines by BS-Seq. 
Using the MeDIP-Seq technology, which allowed me to identify integration 
sites of the virus in the context of HPV+ HNSCC, I showed that integration 
sites across the human genome appear to be random, whereas there is a 
significant enrichment of potential integration sites within the viral E2 (E4 and 
E5) region in line with previous reports in cervical cancer  [190]. In summary, 
the obtained methylation data from the entire HPV type 16 methylome in 
HNSCC may lead the way to the identification of novel diagnostic markers, 
detecting this change in extracted DNA from patients’ saliva or tissue 
samples. 
For the genomic analysis described in chapter 5, paired-end sequencing of 
hybrid-captured DNA, targeting 3,230 exons in 182 genes often mutated in 
cancer was employed. Infinium copy number variation (CNV) profiling, 
Sequenom MassArray sequencing and immunohistochemistry were used for 
the validation of the results. The main results were that HPV+ and HPV- 
HNSCCs clustered into two distinct subgroups. TP53 mutations were 
detected in 100% of HPV- cases and abrogation of the G1/S checkpoint by 
CDKN2A/B deletion and/or CCND1 amplification were found in the majority 
of HPV- tumours. Various mutations within the PI3 kinase (PI3K) signalling 
pathway were found in both groups. These findings strongly support a causal 
role for HPV, acting via TP53 and RB1 pathway inhibition, in the 
pathogenesis of a subset of oropharyngeal cancers. The high frequency of 
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PI3K pathway alterations in both HPV+ and HPV- HNSCCs implicates 
activation of this pathway in oropharyngeal tumourigenesis. Furthermore, 
studies of CDK inhibitors in HPV- disease are warranted. These findings 
indicate that therapeutic stratification according to somatic genomic changes, 
in addition to HPV status, could be the most appropriate management for 
these cancers in the future. 
In chapter 6, methylation data from HPV+ and HPV- HNSCC (chapter 3) 
were integrated with publicly available methylation data on HPV-driven 
cancer (cervical cancer) and smoking-induced cancer (lung cancer). A 
significant overlap of cervical cancer samples and HPV+ HNSCC was 
observed when applying multidimensional scaling, suggesting that HPV 
induces a methylation signature independent of the methylation pattern 
observed between tissues. Integration of obtained genomic data from HPV+ 
and HPV- HNSCC with mutation data from HPV-driven cancer (cervical 
cancer) and smoking-induced cancer (lung cancer) revealed that HPV+ 
HNSCC and cervical cancer, as well as HPV- HNSCC and lung cancer, 
harbour similar mutations which can be regarded as the main driver 
mutations across these cancers.  
On the basis of these findings and having integrated all applicable data into 
the Hanahan and Weinberg model, I present an updated model of HPV-
driven and HPV independent head and neck carcinogenesis in chapter 6.  
It is noteworthy that partially distinct and partially overlapping pathways of 
carcinogenesis appear to play a key role in HPV+ vs. HPV- HNSCC. Loss of 
TP53 function is clearly central in the process of malignant transformation in 
both cancers. Mutations in the TP53 gene are present in 100% of cases in 
my set of HPV- HNSCC samples and have been reported in over 90% of 
SCLC cases [187]. In HPV+ cancers E6 leads to the degradation of TP53. 
Irrespective of the different mechanisms in the two subtypes, both resulting in 
genomic instability, this renders the acquisition of common genomic 
alterations (such as gains and losses of entire chromosomal regions which I 
demonstrated by Infinium CNV profiling of HPV+ and HPV- HNSCC; chapter 
5). One explanation why these regions of gains and losses are present in 
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similar genomic locations in both groups could be that these alterations are 
acquired under the selective pressure being exerted in the same 
microenvironment in which both cancers evolve. In contrast, specific effects 
of HPV on the host genome and epigenome (independent of a loss of TP53 
function and distinct from those present in e.g. smoking-induced HNSCC) 
may be equally important and make HPV+, compared with HPV- HNSCC, 
still appear as a distinct genetic and epigenetic entity. However, it is difficult 
to know which proportion of genetic and epigenetic changes are driving the 
process of malignant transformation and which proportion can be regarded 
as passenger mutations or simple bystanders which do not play any role in 
the process of malignant transformation or in the maintenance of the 
malignant phenotype. It is therefore important to define the specific 
epigenetic and genetic drivers in the future which underlie the spectrum of 
hallmark capabilities [54] acquired by a given cell in the development of these 
subtypes of HNSCC.  
Lastly, the potential of the detected genetic and epigenetic changes to serve 
as a diagnostic biomarker is evaluated. The data clearly show that the 
obtained NGS data are not yet sufficient to cluster HPV+ and HPV- HNSCC 
in 100% of cases. Adding a small panel of candidate epigenetic markers, 
sufficiently clusters these samples into two groups, even if TP53 is excluded. 
Although this current analysis has various limitations, it shows a promising 
future approach towards the development of novel biomarkers by combining 
genetic, epigenetic (and potentially transcriptomic data) which will be 
analysed in extensive sample collections in the course of ongoing cancer 
genome and epigenome initiatives (see chapter 1). This will further boost the 
translation of personalized cancer medicine into clinical practices across the 
world. 
In conclusion, my work has contributed to the understanding of genetic and 
epigenetic changes at oncogenic loci associated with the progression of 
HPV+ and HPV- HNSCC. Only a small number of epigenetic alterations in 
the context of HPV+ and HPV- HNSCC has been described to date. The 
evaluation of the genetic and epigenetic changes, detected by 
comprehensive methylome analysis (both of the host and the viral DNA), 
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genomic analysis and multidimensional analysis of the obtained data with 
publicly available data, in HPV+ HNSCC, compared with HPV- HNSCC, 
represents a major step towards advancing the understanding of both HPV+ 
HNSCC and HPV- HNSCC and may explain the better outcome and survival 
of patients suffering from this distinct subtype. In the longer-term, these data 
can be expected to be used for the identification of potential diagnostic and 
prognostic markers, as well as putative therapeutic targets. 
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9. Appendix 
 
 
Appendix Figure A.1: Maximum Likelihood based phylogenetic tree of 207 PVs as inferred 
from a combined E1-E2-L1 amino acid sequence analysis. PV taxonomic units are indicated 
in Greek letters (‘genera’) and numbers (‘species’: [191]); obtained from [192]. 
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Appendix Figure A.2: Standard curve for GAPDH (slope= -3.264, primer efficiency = 
102.48 %) 
 
 
Appendix Figure A.3: Standard curve for E6 (slope= -3.3683, primer efficiency = 98.1 %). 
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Appendix Figure A.4: Standard curve for E7 (slope= -3.2537, primer efficiency = 102.93 
%). 
 
 
Appendix Figure A.5: Standard curve for L1 (slope= -3.156, primer efficiency = 107.42 %). 
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Appendix Figure A.6: Standard curve for L2 (slope= -3.517, primer efficiency = 92.46 %). 
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Gene name   Gene name 
ABL1 CDK6 FLT4 MEN1 PTPN11   ALK 
ABL2 CDK8 FOXP4 MET PTPRD   BCR 
AKT1 CDKN2A GATA1 MITF RAF1   BRAF 
AKT2 CDKN2B GNA11 MLH1 RARA   EGFR 
AKT3 CDKN2C GNAQ MLL RB1   ETV1 
ALK CEBPA GNAS MPL RET   ETV4 
APC CHEK1 GPR124 MRE11A RICTOR   ETV5 
AR CHEK2 GUCY1A2 MSH2 RPTOR   ETV6 
ARAF CRKL HOXA3 MSH6 RUNX1   EWSR1 
ARFRP1 CRLF2 HRAS MTOR SMAD2   MLL 
ARID1A CTNNB1 HSP90AA1 MUTYH SMAD3   RAF1 
ATM DDR2 IDH1 MYC SMAD4   RARA 
ATR DNMT3A IDH2 MYCL1 SMARCA4   RET 
AURKA DOT1L IGF1R MYCN SMARCB1   TMPRSS2 
AURKB EGFR IGF2R NF1 SMO     
BAP1 EPHA3 IKBKE NF2 SOX10     
BCL2 EPHA5 IKZF1 NKX2-1 SOX2     
BCL2A1 EPHA6 INHBA NOTCH1 SRC     
BCL2L1 EPHA7 INSR NPM1 STAT3     
BCL2L2 EPHB1 IRS2 NRAS STK11     
BCL6 EPHB4 JAK1 NTRK1 SUFU     
BRAF EPHB6 JAK2 NTRK2 TBX22     
BRCA1 ERBB2 JAK3 NTRK3 TET2     
BRCA2 ERBB3 JUN PAK3 TGFBR2     
CARD11 ERBB4 KDM6A PAX5 TNFAIP3     
CBL ERCC2 KDR PDGFRA TNKS     
CCND1 ERG KIT PDGFRB TNKS2     
CCND2 ESR1 KRAS PHLPP2 TOP1     
CCND3 EZH2 LRP1B PIK3CA TP53     
CCNE1 FANCA LRP6 PIK3CG TSC1     
CD79A FBXW7 LTK PIK3R1 TSC2     
CD79B FGFR1 MAP2K1 PKHD1 USP9X     
CDH1 FGFR2 MAP2K2 PLCG1 VHL     
CDH2 FGFR3 MAP2K4 PRKDC WT1     
CDH20 FGFR4 MCL1 PTCH1       
CDH5 FLT1 MDM2 PTCH2       
CDK4 FLT3 MDM4 PTEN       
 
Appendix Table A.1: 182 genes sequenced across entire coding sequence (A) and 14 
genes sequenced across selected introns (B). 
 
A B 
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OncoCarta v1.0  OncoCarta v3.0 
Gene_Assay ID Mutation  Gene_Assay ID Mutation 
ABL1_1 G250E  ABL1_301 M244V 
ABL1_10 F317L  ABL1_302 L248V 
ABL1_11 M351T  AKT1_303 E17K 
ABL1_12 E355G  APC_304 E1306* 
ABL1_13 F359V  APC_305 E1309fs*4 
ABL1_14 H396R  APC_306 APC_E1379* 
ABL1_2 Q252H  APC_307 APC_Q1338* 
ABL1_3 Y253H  APC_308 Q1367* 
ABL1_4 Y253F  APC_309 Q1378* 
ABL1_5 E255K  APC_310 Q1429* 
ABL1_6 E255V  APC_311 R1114* 
ABL1_7 D276G  APC_312 R1450* 
ABL1_8 F311L  APC_313 R876* 
ABL1_9 T315I  APC_314 S1465fs*3 
AKT1_1 rs11555435  APC_315 T1661fs*9  
AKT1_2 rs11555431  BRAF_316 D587A 
AKT1_3 rs11555432  BRAF_317 D587E 
AKT1_4 rs12881616  BRAF_318 D594E 
AKT1_5 rs11555433  BRAF_319 E586K 
AKT1_6 rs11555436  BRAF_320 F595S 
AKT1_7 rs34409589  BRAF_321 G469A 
AKT2_1 S302G  BRAF_322 G466V 
AKT2_2 R371H  BRAF_323 I592M 
BRAF_1 G464R  BRAF_324 I592V 
BRAF_10 F595L  BRAF_325 K601del 
BRAF_11 G596R  BRAF_326 N581S 
BRAF_12-13 (CA) L597S  BRAF_327 R444W 
BRAF_12-13 (CA) L597R  BRAF_328 S605F 
BRAF_12-13 (CA) L597Q  BRAF_329 S605N 
BRAF_12-13 (CA) L597V  BRAF_330 T599_V600insTT 
BRAF_14 T599I  BRAF_331 V471F 
BRAF_15-16 (CA) V600E  BRAF_332 V600A 
BRAF_15-16 (CA) V600K  BRAF_333 V600D 
BRAF_15-16 (CA) V600R  BRAF_334 V600M 
BRAF_15-16 (CA) V600L  CDKN2A_335 E61* 
BRAF_17 K601N  CDKN2A_336 E69* 
BRAF_18 K601E  CDKN2A_337 E88* 
BRAF_2 G464V  CDKN2A_338 R58* 
BRAF_2 G464E  CDKN2A_339 D84Y 
BRAF_4 G466R  CDKN2A_340 R80* 
BRAF_5 F468C  CDKN2A_341 H83Y 
BRAF_6-8 (CA) G469S  CSF1R_342 L301S 
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BRAF_6-8 (CA) G469E  CSF1R_342 L301* 
BRAF_6-8 (CA) G469A  CSF1R_343 Y969C 
BRAF_6-8 (CA) G469V  CSF1R_343 Y969F 
BRAF_6-8 (CA) G469R  CSF1R_344 Y969H 
BRAF_6-8 (CA) G469R  CSF1R_345 Y969* 
BRAF_9 D594V|G  CTNNB1_346 A13T 
CDK_1 R24C  CTNNB1_347 A21T 
CDK_2 R24H  CTNNB1_348 D32G 
EGFR_1 R108K  CTNNB1_348 D32A 
EGFR_10 S768I  CTNNB1_348 D32V 
EGFR_11 V769_D770insASV  CTNNB1_349 G34R 
EGFR_12 V769_D770insCV  CTNNB1_350 G34V 
EGFR_13 D770_N771>AGG  CTNNB1_350 G34E 
EGFR_13 V769_D770insASV  CTNNB1_351 S33C 
EGFR_13 V769_D770insASV  CTNNB1_351 S33F 
EGFR_14 D770_N771insG  CTNNB1_351 S33Y 
EGFR_15 N771_P772>SVDNR  CTNNB1_352 S37A 
EGFR_16 P772_H773insV  CTNNB1_352 S37P 
EGFR_17 H773>NPY  CTNNB1_353 S37F 
EGFR_18 H773_V774insNPH  CTNNB1_353 S37C 
EGFR_18 H773_V774insPH  CTNNB1_353 S37Y 
EGFR_18 H773_V774insH  CTNNB1_354 S45F 
EGFR_19 V774_C775insHV  CTNNB1_354 S45Y 
EGFR_2 T263P  CTNNB1_354 S45C 
EGFR_20 T790M  CTNNB1_355 S45P 
EGFR_21 L858R  CTNNB1_355 S45A 
EGFR_22 L861Q  CTNNB1_356 T41A 
EGFR_3 A289V  CTNNB1_356 T41S 
EGFR_4 G598V  CTNNB1_356 T41P 
EGFR_5 E709K  CTNNB1_357 T41I 
EGFR_5 E709H  CTNNB1_358 T41I 
EGFR_6 E709A  CTNNB1_359 V22_G38del 
EGFR_6 E709G  CTNNB1_360 V22A 
EGFR_6 E709V  CTNNB1_361 W25_D32del 
EGFR_7 G719S  EGFR_362 A750P 
EGFR_7 G719C  EGFR_363 D761N 
EGFR_8 G719A  EGFR_364 D761Y 
EGFR_9 M766_A767insAI  EGFR_365 E734K 
EGFR_M (CA) E746_T751del  EGFR_366 E746_S752>A 
EGFR_M (CA) E746_A750del  EGFR_367 E746_S752>D 
EGFR_M (CA) E746_A750del  EGFR_368 E746_T751>A 
EGFR_M (CA) E746_T751del  EGFR_369 E746_T751del 
EGFR_M (CA) E746_A750del  EGFR_370 E746K 
EGFR_M (CA) E746_T751del, 
S752D 
 EGFR_371 G719D 
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EGFR_M (CA) L747_E749del  EGFR_372 G735S 
EGFR_M (CA) L747_T750del  EGFR_373 G810D 
EGFR_M (CA) L747_S752del  EGFR_374 G810S 
EGFR_M (CA) L747_T751del  EGFR_375 H773R 
EGFR_M (CA) L747_S752del, 
P753S 
 EGFR_376 K745R 
EGFR_M (CA) L747_T751del  EGFR_377 L730F 
EGFR_M (CA) A750P  EGFR_378 L747_P753>Q 
EGFR_M (CA) T751A  EGFR_379 L747_P753>S 
EGFR_M (CA) T751P  EGFR_380 L747_R748>FP 
EGFR_M (CA) T751I  EGFR_381 L747_T751>P 
EGFR_M (CA) S752I/F  EGFR_382 L747_T751>S 
EGFR_M (CA) L747_Q ins  EGFR_381 L747_T751>P 
EGFR_M (CA) E746_T751del, I ins  EGFR_383 L858M 
EGFR_M (CA) E746_A750del, 
T751A 
 EGFR_384 L858R 
EGFR_M (CA) E746_T751del, V ins  EGFR_385 N771_P772>SVDNR 
EGFR_M (CA) E746_A750del, V ins  EGFR_386 P733L 
EGFR_M (CA) L747_E749del, 
A750P 
 EGFR_387 P753S 
EGFR_M (CA) L747_T750del, P ins  EGFR_388 S752_I759del 
EGFR_M (CA) L747_S752del, Q ins  EGFR_389 S752Y 
EGFR_M (CA) T751 Undefined  EGFR_390 T790M 
EGFR_M13R S752_I759del  EGFR_391 V742A 
ERBB2_1 L755P  EGFR_392 W731* 
ERBB2_2 G776S  ERBB2_393 D769H 
ERBB2_2 G776LC  ERBB2_394 V777L 
ERBB2_3 G776VC  FLT3_395 D835del 
ERBB2_6 A775_G776insYVMA  FLT3_396 D835E 
ERBB2_7 P780_Y781insGSP  FLT3_396 D835E 
ERBB2_8 P780_Y781insGSP  FLT3_397 I836M 
ERBB2_9 S779_P780insVGS  HRAS_398 G12R 
FGFR1_1 S125L  HRAS_398 G12C 
FGFR1_2 P252T  JAK3_399 A572V 
FGFR3_3 G370C  JAK3_400 P132T 
FGFR3_4 Y373C  JAK3_401 V722I 
FGFR3_5 A391E  KIT_402 N822K 
FGFR3_6 K650Q  KIT_403 T670I 
FGFR3_6 K650E  KIT_404 V654A 
FGFR3_7 K650T  KRAS_405 A146T 
FGFR3_7 K650M  KRAS_406 G13A 
FLT3_1 I836del  KRAS_407 G13R 
FLT3_2 Control1  KRAS_408 L19F 
FLT3_2 Control2  KRAS_409 Q22K 
FLT3_2 Control3  MET_410 H1112R 
FLT3_3 Control1  MET_411 H1112Y 
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FLT3_3 Control2  MET_412 M1268T 
FLT3_3 Control3  MET_413 T1010I 
FLT3_4 D835H  MET_414 Y1248C 
FLT3_4 D835Y  MET_415 Y1248H 
HRAS_2 G12V  MLH1_416 V384D 
HRAS_2 G12D  MYC_417 A59V 
HRAS_3 G13C  MYC_418 N101T 
HRAS_3 G13R  MYC_419 P260A 
HRAS_3 G13S  MYC_420 P57S 
HRAS_5 Q61H  MYC_421 S77F 
HRAS_5 Q61H  MYC_422 T73I 
HRAS_6 Q61L  PDGFRA_423 D842_D846>E 
HRAS_6 Q61R  PDGFRA_424 D842_D846>G 
HRAS_6 Q61P  PDGFRA_425 D842_D846>N 
HRAS_7 Q61K  PDGFRA_426 D842_M844del  
JAK2_1 V617F  PDGFRA_427 D842_S847>EA 
KIT_1 D52N  PDGFRA_428 D842I 
KIT_10 V559del  PDGFRA_429 D842V  
KIT_11 V559_V560del  PDGFRA_430 D842Y 
KIT_12 V560del  PDGFRA_431 H845_N848>P 
KIT_13.1-13.2 (CA) P551_V555del  PDGFRA_432 R841_D842del 
KIT_14.2 Y553_Q556del  PDGFRA_433 S566_E571>R 
KIT_15 Y570_L576del  PDGFRA_434 S566_E571>R 
KIT_16 E561K  PIK3CA_435 E545A 
KIT_17 L576P  PIK3CA_435 E545G 
KIT_18 P585P  PIK3CA_436 N1068fs*4 
KIT_19 D579del  PIK3CA_437 Y1021C 
KIT_2 Y503_F504insAY  PTEN_438 K267fs*9 
KIT_20 K642E  PTEN_439 K6fs*4 
KIT_21 D816V  PTEN_440 N323fs*2 
KIT_22 D816H  PTEN_441 N323fs*21 
KIT_22 D816Y  PTEN_442 P248fs*5 
KIT_23 V825A  PTEN_443 R130Q 
KIT_24 E839K  PTEN_443 R130fs*4 
KIT_25 M552L  PTEN_444 R130G 
KIT_26 Y568D  PTEN_444 R130* 
KIT_27 F584S  PTEN_445 R173C 
KIT_3 W557R  PTEN_446 R173H 
KIT_3 W557R  PTEN_447 R233* 
KIT_3 W557G  PTEN_448 R335* 
KIT_4 V559D  PTEN_449 V317fs*3 
KIT_4 V559A  RB1_450 C706F 
KIT_4 V559G  RB1_451 E137* 
KIT_5 V559I  RB1_452 E748* 
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KIT_6 V560D  RB1_453 L199* 
KIT_6 V560G  RB1_454 L660fs*2 
KIT_7 K550_K558del  RB1_455 R320* 
KIT_8 K558_V560del  RB1_456 R358* 
KIT_9 K558_E562del  RB1_457 R455* 
KRAS_1-2 (CA) G12V  RB1_458 R552* 
KRAS_1-2 (CA) G12A  RB1_459 R556* 
KRAS_1-2 (CA) G12D  RB1_460 R579* 
KRAS_1-2 (CA) G12C  RET_461 A883F 
KRAS_1-2 (CA) G12S  RET_462 C634R 
KRAS_1-2 (CA) G12R  RET_463 C634W 
KRAS_1-2 (CA) G12F  RET_464 C634Y 
KRAS_4 G13V  RET_465 D631_L633>E 
KRAS_4 G13D  RET_466 D631G 
KRAS_5 A59T  RET_467 D898_E901del 
KRAS_6 Q61E  RET_468 E632_A640>VRP 
KRAS_6 Q61K  RET_469 E632_L633del 
KRAS_7 Q61L  RET_470 E632_L633>V 
KRAS_7 Q61R  RET_471 E768D 
KRAS_7 Q61P  RET_472 F612_C620del 
KRAS_8 Q61H  RET_473 F612_C620del 
KRAS_8 Q61H  RET_474 M918T 
MET_1 R970C  SRC_475 Q531* 
MET_2 T992I  STK11_476 D194N 
MET_3 Y1230C  STK11_477 D194V 
MET_4 Y1235D  STK11_478 E199K 
MET_5 M1250T  STK11_478 E199* 
NRAS_1 G12V  STK11_479 E57fs*7 
NRAS_1 G12A  STK11_480 F264fs*22 
NRAS_1 G12D  STK11_481 G196V 
NRAS_2 G12C  STK11_482 P281fs*6  
NRAS_2 G12R  STK11_482 P281L 
NRAS_2 G12S  STK11_483 P281fs*6  
NRAS_3 G13V  STK11_483 P281L 
NRAS_3 G13A  STK11_484 Q170* 
NRAS_3 G13D  STK11_485 Q37* 
NRAS_4 G13C  STK11_486 W332* 
NRAS_4 G13R  TP53_487 G245S 
NRAS_4 G13S  TP53_488 R175H 
NRAS_5 A18T  TP53_489 R248Q 
NRAS_6 Q61L  TP53_490 R248W 
NRAS_6 Q61R  TP53_491 R273C 
NRAS_6 Q61P  TP53_492 R273H 
NRAS_7 Q61H  TP53_493 R306* 
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NRAS_8 Q61E  VHL_494 F148fs*11 
NRAS_8 Q61K  VHL_495 L158Q 
PDGFRA_1 V561D  VHL_496 L85P 
PDGFRA_10 I843_S847>T  VHL_497 L89H 
PDGFRA_11 D842V  VHL_498 P81S 
PDGFRA_2 T674I  VHL_499 R161* 
PDGFRA_3 F808L  VHL_500 R167W 
PDGFRA_4 D846Y    
PDGFRA_5 N870S    
PDGFRA_6 D1071N    
PDGFRA_7 D842_H845del    
PDGFRA_8 I843_D846del    
PDGFRA_9 S566_E571>K    
PIK3CA_1 R88Q    
PIK3CA_10 H1047Y    
PIK3CA_12 R38H    
PIK3CA_13 C901F    
PIK3CA_14 M1043I    
PIK3CA_14 M1043I    
PIK3CA_2 N345K    
PIK3CA_3 C420R    
PIK3CA_4 P539R    
PIK3CA_5 E542K    
PIK3CA_6 E545K    
PIK3CA_7 Q546K    
PIK3CA_8 H701P    
PIK3CA_9 H1047R    
PIK3CA_9 H1047L    
RET_1 C634R    
RET_2 C634W    
RET_3 C634Y    
RET_4 E632_L633del    
RET_5 M918T    
RET_6 A664D    
 
Appendix Table A.2:  List of mutations of the displayed genes covered on the Oncocarta v1 
and v3 panels (assay TP53_488/R175H did not work in my set of samples). Table kindly 
provided by Sequenom Inc. (Sequenom, US) 
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Appendix Table A.3:  Gene set enrichment analysis on consistent hyper-MVPs. Overlaps 
(‘nOVERLAP’) between the detected gene set and gene sets in the Molecular Signatures 
Database v3.0 (MSigDB; Broad Institute of MIT and Harvard, US) were computed as 
described previously (Subramanian, Tamayo, et al.; PNAS; 2005; 102; 15545-15550). The 
top 30 hits are illustrated. 
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Appendix Table A.4:  Gene set enrichment analysis on consistent hypo-MVPs. Overlaps 
(‘nOVERLAP’) between the detected gene set and gene sets in the Molecular Signatures 
Database v3.0 (MSigDB; Broad Institute of MIT and Harvard, US) were computed as 
described previously (Subramanian, Tamayo, et al.;PNAS; 2005; 102; 15545-15550). The 
top 10 hits are illustrated. 
